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                                        ABSTRACT 
 
 
Diisocyanates (dNCO) such as methylene diphenyl diisocyanate (MDI) are used 
primarily as cross-linking agents in the production of polyurethane products such as 
paints, elastomers, coatings and adhesives, and are the most frequently reported cause of 
chemically induced immunologic sensitization and occupational asthma (OA). Immune 
mediated hypersensitivity reactions to dNCOs include allergic rhinitis, asthma, 
hypersensitivity pneumonitis and allergic contact dermatitis. 
 There is currently no simple diagnosis for the identification of dNCO asthma due 
to the variability of symptoms and uncertainty regarding the underlying mechanisms. 
Immunological sensitization due to dNCO exposure is traditionally thought to require 
initial conjugation of the dNCO to endogenous proteins to generate neoantigens, which 
trigger production of dNCO specific T lymphocytes and ultimately dNCO specific IgE. 
Testing for dNCO-specific IgE, for diagnosis of dNCO asthma is however, only specific 
(96–98%) but not sensitive (18–27%). The low prevalence of detectable dNCO specific 
IgE has been attributed to both assay limitations and a potential IgE-independent dNCO 
asthma mechanism(s). The identity of the conjugated proteins responsible for the 
sensitization also remains unknown. It is also not clear whether dNCOs bind to 
extracellular, cell membrane, or intracellular proteins as a way of triggering non-IgE 
asthma. Standardization and optimization of immunoassays used to screen for dNCO 
specific antibodies in sera is important if its utility as a dNCO asthma diagnostic tool is to 
be achieved. This will potentially improve sensitivity and allow comparison of results 
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across studies. Current studies on assays of dNCO-specific IgE and IgG lack or have 
limited characterization of the conjugates used. 
 Diisocyanates bound to hemoglobin (Hb), human serum albumin (HSA), and 
THP-1 proteins were quantified by HPLC with fluorescence detection. Proteomic tandem 
mass spectrometry (MS) was used to delineate TDI and MDI specific amino acid binding 
sites on Hb as well as identification of proteins from MDI exposed THP-1 cells. The 
trinitrobenzene sulfonic acid assay (TNBS) and SDS gel electrophoresis were used to 
evaluate extent of intra and intermolecular cross-linking in dNCO-HSA conjugates. 
Binding of monoclonal antibodies (mAbs) to dNCO bound proteins in enzyme-linked 
immunosorbent assay (ELISA) was used to evaluate antigenicity of dNCO-protein 
conjugates. 
 The amount of dNCO binding to HSA and Hb increased with the concentration of 
the dNCO used for conjugation. All the dNCOs reacted with HSA more than with Hb. 
Eight binding sites were observed with both MDI and TDI on Hb. The N-terminal valines 
of both the alpha and beta subunits on Hb, lysine 40 of the alpha subunit and lysine 61 of 
the beta subunit were common binding sites for both TDI and MDI. Lysine 7 of the alpha 
subunit and lysines 8, 65 and 66 of the beta subunit were unique to MDI. On the other 
hand, lysines 11, and 16 of the alpha subunit and lysines 17 and 144 of the beta subunit 
were unique to TDI. Protein bound MDI was detected in a dose-dependent manner in 
membrane and cytoplasm fractions of MDI exposed THP-1 cells. MDI was also detected 
in 11 of the 13 cytoplasmic protein bands. The extent of MDI intracellular protein 
binding was not affected by cytochalasin D, a chemical that binds actin filaments and 
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inhibits active uptake into cells. The extent of cross-linking shown using the TNBS assay 
was found to increase with amount of dNCO used. Clear bands from both intra and 
intermolecular cross-linking were observed on all dNCO-Hb/HSA SDS gels. Using 
ELISA, both TDI-Hb and TDI-HSA conjugates were reactive to monoclonal antibodies 
produced against TDI conjugated HSA indicating that dNCO-Hb is also antigenic.  
 The best characterization of dNCO-protein conjugates is achieved by the 
quantitative determination of conjugated dNCO per mole of protein as well as 
determining the extent of dNCO cross-linking. Although HSA is more reactive to dNCOs 
than other serum proteins such as Hb, contribution from other serum proteins to 
development of OA should not be overlooked as dNCO-Hb was found to be reactive to 
dNCO specific mAbs. dNCO-conjugated proteins identified in the soluble fraction of 
MDI exposed THP-1 cells were all of intracellular origin suggesting that MDI can cross 
the cell membrane and react with intracellular proteins. The entry of MDI into live cells 
is a passive process, as the extent of intracellular binding was not affected by 
cytochalasin D. The present study support the potential involvement of dNCO-haptenated 
membrane and intracellular proteins in development of non-IgE dNCO asthma. 
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                                          CHAPTER 1 
                                      INTRODUCTION 
1.1 Industrial and commercial uses of isocyanates 
Diisocyanates (dNCO), characterized by the very highly reactive N=C=O group, are 
used primarily as cross-linkers in the production of polyurethane products such as 
paints, elastomers, coatings, and adhesives1. The most commonly used monomeric 
diisocyanates include methylene diphenyl diisocyanate (MDI), 2, 4 and 2,6-toluene 
diisocyanate (TDI) , and hexamethylene diisocyanate (HDI)2 . Other less commonly 
used diisocyanates include naphthalene diisocyanate (NDI), methylene bis-
cyclohexylisocyanate (HMDI) (hydrogenated MDI), and isophorone diisocyanate 
(IPDI). Examples of widely used polyisocyanates include MDI and TDI based 
polyisocyanates, HDI biuret, and HDI isocyanurate. MDI is increasingly replacing 
TDI in the production of flexible and rigid foams, particle board and wood binders, 
paints and coatings, adhesives, sealants, elastomers and spandex fibers 3. It is also used 
for consolidating loose rock zones in coal mining or tunneling.  
 
During production of polyurethane products, the NCO group reacts with hydroxyl 
groups to form the polyurethane polymers until essentially all available NCO groups 
have reacted. This process is called ‘curing’.  Some products contain free NCO groups 
and are meant to undergo the curing process during use. Adhesives are a good 
example of dNCOs that will undergo curing during use. These are applied in an 
uncured form and bind to wood as they cure. There are also certain products such as 
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mattresses, pillows, and bowling balls, which contain already cured NCO groups 
before they are sold. Cured dNCOs are usually considered less toxic because they do 
not contain free NCO groups 4. The curing reaction in most cases leaves sequestered 
pockets of unreacted NCO groups, which potentially pose a risk of dNCO exposure. 
Diisocyanates are used in settings, such as construction (adhesives, home insulation), 
and the automotive industry (paints and truck bed liners), where an end-use curing 
process is part of the functional performance of the product. These pose greater risk of 
exposure to dNCO. There is an increasing availability of uncured dNCO to both the 
professional applicator, as well as the do it yourself (DIY) consumer. The use of 
polyurethane foam for insulation is increasing as federal and state government 
programs create incentives for their use in increasing energy efficiency. Pour-in-place 
(PIP), spray polyurethane foam (SPF) and one-component foam (OCF) cans are used 
in the arts industry for sculpture and mold making. Auto refinishing and repair, marine 
leisure craft maintenance and repair, and floor and deck maintenance and repair, all 
use uncured polyurethane products. Polyurethane coatings are used to seal concrete 
and refinish floors. Polyurethane sealants are used for glass installation of windshields 
and side windows. Adhesives are used domestically for woodworking and 
bookbinding. All these are dNCO-containing products that pose risk of exposure to 
workers and end users. US federal agencies such as OSHA and NIOSH acknowledge 
the health risks resulting from occupational exposure to dNCOs and have established 
occupational exposure limits that are supposed to be protective to workers over an 8 hr 
time weighted average working shift. The OSHA mandated permissible exposure 
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limits (PEL) for TDI and MDI are 0.02 ppm as ceiling levels. The NIOSH 
recommended exposure limits (REL) for these two dNCOs are currently set as 5 ppb.  
1.2 Chemistry of diisocyanates 
Diisocyanates are highly reactive electrophilic compounds that undergo nucleophilic 
addition reactions with a variety of nucleophiles such as amines, alcohols, and thiols. 
Under physiological conditions, isocyanates would have the following order of 
reactivity with the various nucleophiles: sulfhydryl’s >> primary amines > secondary 
amines >   hydroxyls5.Figure 1.1 illustrates the various reactions an isocyanate would 
undergo with nucleophilic compounds. 
 
 
Figure 1.1: The general chemical reactions of isocyanates  
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1.3 Reaction pathways in the biological system 
In the biological environment, MDI can undergo several reactions6. Its reaction with 
biomolecules to form adducts is of particular interest. Several biomolecules in the 
biological environment are found that possess hydroxyl, amino, and sulfhydryl groups. 
MDI can react with these biomolecules after entry into the body. As Figure 1.2 shows, 
apart from its conjugation to biomolecules, two MDI molecules can also react to form 
MDI urea. Further addition of more MDI molecules to the MDI urea results in MDI 
polyurea. Another significant competing reaction is MDI’s autohydrolysis in aqueous 
environments to form methylene dianiline (MDA), which is the corresponding 
diamine from MDI. Because of the abundance of nucleophiles in the physiological 
environment and high chemical reactivity of diisocyanates, it can be assumed that no 
unreacted diisocyanates circulate in the body after absorption.  
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Figure 1.2: Reaction pathways of MDI in biological systems. 
 
1.4 Health Effects of MDI Exposure 
Both the respiratory tract and skin are potential routes of dNCO exposure. Although 
MDI has a low vapor pressure, it becomes airborne during spraying operations and 
typically exists as particles or aerosols. Studies have also shown that dermal contact to 
dNCO can induce respiratory tract sensitization in animals7. A follow up survey of 
new workers exposed to liquid MDI demonstrated an increased risk for developing 
new onset asthma-like symptoms8. Isocyanate-containing product breakdown or 
leaching have been raised as potential sources of diisocyanate exposure to the public9.  
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1.4.1 Inhalation Exposure 
4, 4’-MDI is a solid at room temperature and has a very low vapor pressure (≤0.01 
Pa). MDI containing polyurethane products that require mixing of the MDI with 
polyols and then spraying at the site of application pose the greatest risk of inhalation 
exposure 10,11.   
1.4.2 Dermal exposure 
Dermal exposure to MDI in workers has been well-documented 8,12,13. Dermal 
sensitization to MDI has been reported in animal studies 14,15. In domestic settings, 
dermal exposure to MDI from use of do it yourself (DIY) products is possible. Due to 
the presence of MDI in polyurethane based paints, adhesives and coatings, dermal 
exposure can occur during both spraying and other application type operations and at 
times in domestic settings by coming in contact with a product before it completely 
cures. 
1.4.3 Hypersensitivity 
Diisocyanates are the most frequently reported cause of chemically-induced 
occupational asthma (OA) and are capable of producing both immune- and irritant-
mediated asthmas 16,17. The prevalence of diisocyanate asthma among exposed 
workers ranges from 5 %-15 %17. Over 200,000 workers are directly employed in the 
production and use of isocyanates worldwide in various industries18 and millions more 
are potentially exposed through use of dNCO containing products. MDI is one of the 
dNCOs known to cause occupational asthma. Common direct toxicities of dNCO 
exposure include respiratory19, dermal and mucous membrane irritation. Immune-
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mediated hypersensitivity reactions to dNCOs include allergic rhinitis20, asthma, 
hypersensitivity pneumonitis21,22 and allergic contact dermatitis23. Despite MDI 
accounting for approximately 60% of the dNCO global market, most of the published 
biomedical dNCO research studies have used toluene diisocyanate (TDI). This is 
possibly because of two reasons (i) from about 15 years ago and back, TDI was the 
most used diisocyanate and so researchers were more interested in evaluating effects 
of exposure to TDI. There was a shift in the market from TDI to MDI use because 
MDI, being less volatile than TDI, was conceived to pose a lesser risk of exposure 
than TDI, and (ii) MDI’s lower vapor pressure, not only made respiratory exposure 
less likely, but is technically more challenging to conduct animal inhalation exposure 
studies24,25.  MDI is a known respiratory sensitizer based on reported animal and 
human studies. In humans, health effects due to respiratory hypersensitivity to MDI 
can range from asymptomatic, mild respiratory symptoms, to severe responses such as 
hypersensitivity pneumonitis or severe asthma. Death from severe asthma in sensitized 
subjects has been reported19. 
 
1.5 Reaction mechanisms of protein binding. 
Immunologic MDI sensitization and OA is commonly believed to require initial 
conjugation of MDI to endogenous proteins to generate neoantigens26.These 
complexes are recognized by antigen presenting cells; leading to the production of 
dNCO-specific T-lymphocytes and some dNCO-specific B-lymphocytes that mature 
to dNCO-specific IgE secreting plasma cells. However, the functional form of the 
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antigens responsible for sensitization reactions are still unknown. Methylenediphenyl 
diisocyanate- haptenated human serum albumin (MDI-HSA) is used to measure 
specific anti-MDI antibody in workers, but these haptenated proteins are usually 
poorly characterized. Diisocyanates are reactive, bi-functional electrophilic 
compounds. When reacted with proteins under aqueous conditions they can covalently 
bind to protein amines and reversibly to thiols27. Multiple species are formed when 
dNCOs react with proteins as demonstrated by the MDI-albumin reaction products 
depicted in Figure 1.3. It must also be noted that a single protein molecule such as 
human serum albumin may be haptenated at multiple nucleophilic sites to produce one 
or more of the species noted in Figure 1.3 28.  
 
Figure 1.3: Reaction products of human serum albumin with MDI. [1] Monomeric 
dNCO binding, [2] Intra-molecular crosslinking, [3] polymeric binding onto a protein 
site, and [4] Inter molecular crosslinking.   
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1.6 Development of occupational asthma 
Occupational asthma (OA) is a complex disease  with genetic, behavioral and 
environmental factors 29. OA is a type of asthma that is caused by conditions 
attributable to a particular work environment. There are essentially two types of OA: 
immunologic OA which is characterized by an asymptomatic latency period of 
exposure necessary for acquiring immunologic sensitization, and non-immunologic 
OA, which has no latency period and occurs upon exposure to high concentrations of 
irritants 30. Occupational sensitizers are either high molecular weight (HMW, e.g. 
proteins) or low molecular weight (LMW) compounds which induce asthma by 
producing specific IgE antibodies or possibly trigger other immune cell mediated 
mechanisms. HMW agents act as complete antigens, whereas LMW chemicals, such 
as MDI, must first react with autologous proteins to produce a functional allergen 21,31. 
Agents that are of insufficient volume to be allergenic and must bind covalently to a 
protein to become allergens are referred to as haptens. The fate of diisocyanate in the 
body and the ultimate antigenic form(s) are unknown 32. Haptenation to proteins is 
believed to be the initial step for these sensitization reactions.  
 
Diisocyanates do not consistently induce specific IgE antibodies 33,34. Therefore 
testing for dNCO-specific IgE for diagnosis of dNCO asthma is specific (96-98%), but 
insensitive (18-27%). One possible explanation is that sensitization of the respiratory 
tract by dNCO can be achieved by more than one immunologic mechanism, including 
some that are IgE independent. Another possibility is that assay methods currently 
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being used are not sensitive enough to detect certain low levels of anti-dNCO-IgE. 
There are several issues with immunoassays being used, (i) most of them do not report 
characterization of the HSA-MDI conjugates used to detect MDI specific IgE, (ii) 
most still do not report how the conjugates were prepared, and (iii) some misinterpret 
results from the characterization of the HSA-MDI conjugates. It is worth noting also 
that the circulating life of specific IgE is 2.5 days but after cessation of exposure,  IgE 
antibody is detected between 4 months and 2 years 2,35. The observation that dNCO 
asthma has similar clinical and pathologic features of atopic disease, but that it is not 
consistently associated with production of specific IgE or up-regulation of IgE 
receptors 36 suggests the involvement of IgE-independent immune mechanisms 
including cell-mediated and mixed reactions. The figure below shows the possible 
ways by which OA and hypersensitivity reactions can develop upon MDI exposure. 
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Figure 1.4: Possible mechanism(s) leading to the development of hypersensitivity 
reactions and OA upon MDI exposure. 
 
 
OA can also develop through a non-immunologic mechanism (irritant-induced 
asthma). This occurs when an individual is exposed to high concentrations of 
respiratory irritants resulting in injury to the epithelial system. The main target of 
injury, though not yet identified, could be bronchial epithelium which, when denuded, 
exposes nerve endings resulting in neurogenic inflammation, loss of relaxing epithelial 
factors, release of inflammatory mediators and pro-inflammatory cytokines, secretion 
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of growth factors for epithelial cells, smooth muscle cells, fibroblasts and matrix 
degradation 37-39. 
1.7 Diagnosis of diisocyanate asthma 
There is currently no simple way to diagnose diisocyanate asthma due to the 
variability of symptoms, the uncertainty regarding the underlying mechanisms, and the 
multiple other potential occupational and environmental causes of a worker’s asthma. 
Diisocyanate asthma, in general, displays the same pathological hallmarks of high 
molecular weight (protein) allergic asthmas, including eosinophilic inflammation and 
increased airway reactivity. This prompted researchers to suggest the use of dNCO-
specific IgE for dNCO asthma diagnosis. The role of IgE in the underlying 
pathophysiology of dNCO asthma is however a matter of debate28. Ott et al 40 
discussed the issues surrounding immunoassay standardization and variability of 
antigenicity of dNCO haptenated protein preparations which are central to both asthma 
diagnosis and questions of pathophysiological mechanism(s). Diisocyanate 
haptenation and characterization of resultant antigens remains problematic. This is due 
to the high reactivity and divalent nature of dNCOs, resulting in self-polymerization, 
intramolecular and intermolecular protein crosslinking. 
 
The main challenge in the diagnosis of dNCO sensitization is that current methods are 
not sufficiently sensitive (25% for IgE and 43% for IgG – Specific IgG is considered a 
marker of exposure rather than disease) 40, and the  actual prevalence of dNCO-
specific IgE reported in studies varies greatly41.  There are also multiple other 
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potential occupational and environmental causes of asthma. It can be difficult to 
distinguish diisocyanate asthma from irritant aggravation of underlying asthma. The 
major tools are clinical history including exposure questionnaire; spirometry and non-
specific inhalation challenge. Methacholine challenge is used to identify hyperactive 
reactive airways, a hallmark of asthma.  Lack of hyperreactive airways is used to rule 
out asthma.  False negatives are common if subjects are on corticosteroids. Although 
documenting the relationship between symptoms and work can be helpful, it is more 
reliable at excluding rather than confirming a diagnosis29. Specific broncho 
provocation testing (SBPT) with a diisocyanate in a specialized inhalation challenge 
laboratory is regarded as the gold standard for dNCO asthma diagnosis. This is, 
however, an expensive and technically difficult technique that is mainly used for 
research purposes in the United States and even so, the method is neither 100% 
sensitive nor specific33,42,43. Measurements of peak expiratory flow rates (PEFR) at 
and away from exposure environment has been used for diagnosis of dNCO asthma 
30,31. However, sensitivity ranges from 70 %-100 % and specificity from 50 %-100 % 
against SBPT32,34. 
1.8 Methods for characterization of MDI-protein adducts 
There are several methods that have been used to characterize dNCO-protein 
conjugates 35,36  for standardization of dNCO-specific antibody detection 
immunoassays and also for biomonitoring assays of dNCO exposure. Some high 
performance liquid chromatographic (HPLC) and gas chromatographic (GC) methods 
have been developed and used which involve use of electrochemical and mass 
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detection37,44 for biomonitoring of dNCOs exposure by measuring their respective 
hydrolysis amine products following strong acid or base treatment. These are 
expensive methods that have limited application, as they do not provide qualitative 
information. The trinitrobenzene sulfonic acid (TNBS) assay has also been used for 
characterization of dNCO-protein conjugates and results have often been 
misinterpreted. The TNBS assay is based on loss of a protein’s primary amine 
reactivity with TNBS after haptenation. Since amines are the most observed sites of 
dNCO conjugation on proteins, some investigators have taken the absolute loss of 
amine reactivity to TNBS as a quantitative marker of moles of dNCO bound per mole 
of protein.  Although this may be a good approximation with mono-isocyanates, with 
dNCOs, there is a high likelihood of conjugation of one isocyanate moiety with 
subsequent hydrolysis of the other isocyanate to regenerate a primary amine (Fig 1.3). 
In this case, there would be no net loss of amine causing an underestimation of moles 
dNCO bound by the TNBS assay.  Alternatively, if dNCO polymerizes onto itself the 
TNBS will underestimate the total amount of dNCO bound. The TNBS assay, when 
used in conjunction with other analytical methods is a better indicator of cross-linking 
(intra- and intermolecular) than of total dNCO bound.  Polyacrylamide gel 
electrophoresis and Western blot analyses provide more qualitative assessment of the 
dNCO conjugates, but are generally of poor resolution and at best semi-quantitative.   
 
OA induced by MDI has been described in workers in which MDI-specific IgE can be 
measured and more often in which immunoassay for MDI-specific IgE is negative8.   
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Considerable findings from both human and animal studies suggest that an alternative 
immune-mediated (possibly Th-1 or CD8+) mechanism(s) of dNCO asthma may be 
involved, suggesting that the target haptenated proteins may be intracellular or 
membrane bound. 45-48. Recent studies suggest involvement of T-lymphocytes in 
diisocyanate asthma rather than through induction and suppression of IgE synthesis as 
T-lymphocytes release potent cytokines causing direct inflammation 49,50. CD8+ T cell 
numbers increase in the peripheral circulation of diisocyanate asthmatics following 
workplace exposure 51. CD8+ T cell clones from two diisocyanate asthmatics 
exhibited a mixed Th1/Th2-like phenotype and secreted high levels of both IFN-γ and 
IL-5 but not IL-4, contrary to the profile of T cell clones that are preferentially 
expanded from atopic individuals, which are primarily CD4+ and produce IL-4 and 
IL-5 but not IFN- γ46,52. 
 
 As noted above, there are knowledge gaps with respect to the ultimate allergenic 
haptenated proteins, and mechanisms of asthmatic sensitization.  Better methods of 
characterizing MDI-haptenated proteins used for antibody detection and evaluation of 
the ability of MDI to bind both cell membrane and intracellular proteins would 
provide data that would help address these knowledge gaps.    
 
The specific objectives addressed in this thesis are (i) Development of sensitive and 
specific method(s) for quantitative evaluation and characterization of MDI-protein 
conjugates, (ii) Evaluation of historical methods for characterization of dNCO-protein 
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conjugates, (iii) Mapping out specific MDI and TDI binding sites on Hb using 
proteomic analysis of tryptic peptides from MDI-protein conjugates, (iv) 
Demonstration of MDI binding to proteins in cellular fractions of exposed THP-1 
cells, (v) Identification of proteins from THP-1 cells. 
                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
                                                  CHAPTER 2 
 
                 INSTRUMENTATION, MATERIALS AND METHODS 
 
2.1 INSTRUMENTATION 
2.1.1 Mass Spectrometry 
Electrospray ionization mass spectrometry (ESI- MS) detects small mass shifts in large 
biomolecules making it a very useful tool for studying protein haptenation. Tandem 
mass spectrometry enables the acquisition and structural elucidation of both native and 
modified proteins and peptides. The technique is also very useful for identification of 
unknown proteins from complex protein mixtures. ESI-MS was employed in this 
project for both identification and characterization of modified proteins due to dNCO 
conjugation as well as identifying unknown proteins from dNCO exposed THP-1 cells. 
2.1.2 Electrospray Ionization 
The mass spectrometer used in these studies was a Micromass QTOF-II (Waters 
Corporation, Milford, MA) quadrupole time-of-flight mass spectrometer (qTOF-MS). 
Analyte ions were generated by positive-mode electrospray ionization (ESI). The ESI 
involves droplet formation, droplet shrinkage and gaseous ion formation 53,54. Tryptic 
peptides were separated on a Waters nanoACQUITY UPLC system (Waters 
Corporation, Milford, MA, USA). Positive ion nanoelectrospray was performed using 
10-µm Pico-Tip (Waters) emitters held at a potential of +3.5 kV. The cone voltage was 
held constant at +40 V for all experiments. Dry nitrogen desolvation gas was supplied 
to the instrument via a nitrogen generator (NitroFlowLab, Parker Hannifin, Haverhill, 
MA, USA). [Glu]1-Fibrinopeptide B (100 fmol/µl in 75:25 A/B) was supplied to an 
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orthogonal reference probe55. Ultra-high purity (UHP) argon was used as collision gas. 
The collision energy was set to 6 eV (1-s low energy scan) and a 15- to 30-eV ramp (1-s 
high energy scan).  
2.1.3 High Performance Liquid Chromatography (HPLC) 
For quantification of MDI binding in pure proteins and THP-1 cell fractions, Reverse 
Phase High Performance Liquid Chromatography (RP-HPLC) was employed. 
Following hydrolysis, extraction and derivatization of the amine hydrolysis product, the 
resulting fluorescent complex was injected onto a SUPELCO discovery C18 column at 
1ml/min and analyzed on a Shimadzu Prominence HPLC system consisting of an online 
vacuum degasser (model DGU-20A5), a quaternary pump (model LC-20AT), an auto 
sampler (model SIL-10AD-VP) and a fluorescence detector (model RF-10AXL). The 
HPLC system is controlled by EZStart software version 7.3. The resulting MDA-
fluorescamine complex was excited at 410 nm and emission measured at 510 nm. 
2.1.4 Spectrophotometry 
The extent of cross linking using the TNBS assay was evaluated using 
ultraviolet/visible light (UV/Vis) on a Beckman Coulter spectrophotometer (model DU 
800, Beckman Coulter, Somerset, NJ, USA). The spectrophotometer was interfaced to 
an IBM PC computer and used the DU Series 800 Software (Fullerton, CA). Path length 
of the cuvette was 1 cm.  
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2.2 MATERIALS 
2.2.1 Chemicals 
Unless otherwise specified, all reagents were acquired from Sigma–Aldrich (St. Louis, 
MO, USA) and used without further purification. Ethyl acetate (reagent grade) was 
purchased from J.T. Baker/ Avantor Performance Materials (Center Valley, PA, USA). 
Sodium tetraborate, sodium hydroxide, hydrochloric acid, dialysis membranes, 
molecular weight cut-off (MWCO) of 12,000–14,000, 98% sulfuric acid, and N acetyl 
glycine were purchased from Fischer Scientific (Fair Lawn, NJ, USA).  
 
Abbreviati
on 
Name CAS # Structure 
4,4’-MDI 4,4 Methylene 
Diphenyl 
Diisocyanate 
 
101-68-8 
 
2,4-TDI 2,4 Toluene 
Diisocyanate 
 
584-84-9 
 
1,6-HDI 1,6 
Hexamethylen
e Diisocyanate 
 
822-06-0 
 
 
Figure 2.1: Chemical structures for the isocyanates conjugated to carrier proteins. 
 
2.3 METHODS 
2.3.1 Preparation of dNCO–protein adducts  
MDI-HSA/Hb conjugations 
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MDI–protein adducts were prepared as described previously55. Briefly, protein solutions 
were prepared in 0.1 M PBS (pH 7.4) at 0.5 mg/ml. MDI was dissolved in dry acetone 
at 1.8, 9, 18, and 72 µg/ml for HSA conjugation and at 1.84, 9.2, 18.4, and 73.6 µg/ml 
for Hb conjugation immediately before use. Each MDI solution was added at 34.5 µl to 
5 ml of 0.5 mg/ml protein with mixing, resulting in MDI-protein molar ratios of 1:1, 
5:1, 10:1, and 40:1. Samples were then incubated at room temperature (RT) for 1 h with 
vortexing. Following incubation, samples were dialyzed for 18 h against 4 L of distilled 
deionized water using 12,000 to 14,000 MWCO dialysis tubing (Sigma–Aldrich). The 
samples were stored at 20˚C until analysis. 
TDI-HSA/Hb conjugations 
For preparation of TDI–protein adducts, protein solutions were prepared in 0.1 M PBS 
(pH 7.4) at 0.5 mg/ml. 42.3 µl of TDI were dissolved in 1 ml dry acetone and diluted 
ten-fold to make stock solution for the 40:1 TDI: protein. Serial dilutions of TDI in 
acetone were prepared to make solutions for 10: 1, 5: 1 and 1: 1 TDI: protein. Each TDI 
solution (50µl) was added to 5 ml of 0.5 mg/ml protein with mixing, resulting in TDI: 
protein molar ratios of 1:1, 5:1, 10:1, and 40:1. Samples were incubated and dialyzed as 
described in section 2.3.1 above.  
HDI-HSA/Hb conjugations 
For preparation of HDI–protein adducts, protein solutions were prepared in 0.1 M PBS 
(pH 7.4) at 0.5 mg/ml. A 47.3 µl aliquot of HDI was dissolved in 1 ml dry acetone and 
diluted ten times to make stock solution for the 40:1 HDI: protein. Serial dilutions of 
HDI in acetone were prepared to make solutions for 10: 1, 5: 1 and 1: 1 HDI: protein. 
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50 µL of the HDI solution was added to 5 ml of 0.5 mg/ml protein with mixing, 
resulting in HDI/protein molar ratios of 1:1, 5:1, 10:1, and 40:1. Samples were 
incubated and dialyzed as described previously.  
 
2.3.2 THP-1 MDI Conjugations 
THP-1 cell culture and MDI exposure 
THP-1 monocytic cells (ATCC, Rockville, MD) were cultured in RPMI 1640 (Life 
Technologies) containing 4mM L-glutamine, 25mM HEPES, 50µM ß-mercaptoethanol, 
10% FBS, and 1% antibiotic/antimycotic solution. After sufficient cell replication, the 
cells were harvested by centrifuging at 300 g for 10 min. The RPMI culture media was 
discarded and the cell pellet washed two times with Hanks buffer (+Glucose, + calcium, 
+ magnesium) and the cells were resuspended in the same buffer. Viability and cell 
count were determined before and after exposure to MDI and maintained above 75 %. 
Viability was measured using trypan blue. Fifteen million cells suspended in 2 ml of 
Hanks buffer were exposed to MDI 5 µM, 10 µM, 25 µM, 50 µM and 100 µM MDI 
prepared in 20 µL of ethylene glycol dimethyl ether (EGDE). The MDI was added drop 
wise with vortexing and samples were incubated at 37⁰ C and 5% CO2 (model 370 
Steri-Cycle CO2 incubator, Forma Scientific Inc., Marietta, OH) for 4 hrs. Cells were 
spun down to remove the incubation media (Hanks buffer) and washed two times with 
Hanks buffer. Cells were stored as a pellet at -20⁰ C until further analysis. 
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Effect of exposure times on THP-1-MDI conjugations 
The effect of exposure time on the extent of conjugation of THP-1 cells was studied by 
exposing 15 million cells in a total volume of 2 ml Hanks buffer to 100 µM MDI 
prepared in EGDE for different time durations (30 min, 1 hr, 2 hr, and 4 hr). MDI was 
added drop wise with vortexing and samples were incubated at 37 ⁰ C and 5 % CO2. 
Samples were processed post exposure as described previously.  
2.3.3 THP-1 exposure controls 
Different control experiments were performed to confirm whether MDI crosses cell 
membranes and react with both membrane and intracellular proteins. 
 
THP-1, Cytochalasin D and MDI controls 
Cytochalasin D is a chemical that binds actin filaments and inhibits active uptake of 
substances into cells. THP-1 cells were incubated with 10 µM cytochalasin D for 1 hr 
and exposed to 50 µM MDI for 4 hours. Cells were processed as previously described. 
 
THP-1 and MDA  
THP-1 cells were exposed to 100µM MDA prepared in EGDE. This was performed to 
assess the effectiveness of the washing process to get rid of any MDA that is not 
conjugated to proteins. After incubation, samples were processed as previously 
described.  
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THP-1 and EGDE 
The effect of the organic solvent used for conjugation on cell viability was determined 
by co-incubation of THP-1 cells with 1% EGDE for 4 hr at 37 ⁰C and 5 % CO2. After 
incubation, cell count and viability were measured. Cells were processed as described 
previously. 
 
2.3.4 Protein estimation 
Two approaches were used to extract proteins from MDI-exposed THP-1 cells, 
differential centrifugation and use of protein extraction kits. Differential centrifugation 
at 300 g separates the membrane fraction (debri) from the cytoplasm fraction 
(supernatant). Membrane and cytoplasm protein extraction kits (Fischer scientific) were 
also used to selectively extract proteins from the membrane and cytoplasm fractions. 
Protein determinations were performed on the conjugates by measuring absorbance at 
280 nm on a nano-drop spectrophotometer. 
 
2.3.5 The TNBS assay 
The TNBS reagent assesses, primarily, chemical adduction with primary amines of 
amino acids 56,57 on the surface of proteins. TNBS produces an absorbance shift at 420 
nm upon binding to a primary amine.  The trinitrobenzene sulfonic acid (TNBS) assay 
was performed on HSA and MDI–HSA conjugates. HSA and HSA conjugates were 
diluted in 0.1 M sodium tetraborate (pH 9.3). TNBS (5%, w/v) was diluted 1:5.48 with 
0.1 M borate buffer. To 500 µl of samples, 12.5 µl of TNBS was added, mixed well, 
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and left to react for 30 min. Absorbance at 420 nm was measured on a Beckman Coulter 
spectrophotometer (model DU 800, Beckman Coulter, Somerset, NJ, USA). Hb has a 
strong absorbance at 420 nm that prevents measurement of primary amine content by 
TNBS. 
 
2.3.6 Hydrolysis and extraction 
dNCO-protein conjugates 
Diisocyanate conjugated proteins were hydrolyzed by incubating in 3 M H2SO4 at 100 
°C for 16 hr. MDA, TDA or HDA spiked proteins were run in parallel as external 
calibration standards to the respective dNCO adducted proteins.  Following hydrolysis, 
samples and standards were cooled to room temperature and 5 mL of saturated sodium 
hydroxide added. The samples were vortexed and incubated in an ice bath for 10 
minutes. 6 mL of organic solvent, ethyl acetate (for MDI) or dichloromethane (for TDI 
and HDI) were added to the samples, vortexed for 1 min and left standing at room 
temperature for 1 hr. A 4 mL portion of the organic solvent was then collected and 
evaporated to 1 mL at 40 °C under N2. To the organic solvent, 500 µL of 0.5 % H2SO4 
were added and vortexed for 1 min. The sample was vortexed for an additional 10 
minutes and left standing for 10 minutes. 400 µL of the 0.5 % H2SO4 were collected for 
derivatization.  
2.3.7 Derivatization and HPLC analysis 
To derivatize the extracted diamines for HPLC analysis, 250 µl of saturated borate 
buffer (pH 8.5) and 450 µl of acetonitrile were added to 250 µl of 0.5% H2SO4 extract 
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with MDA, TDA or HDA. This was vortexed for 1 min, and 50 µl of 14.4 mg/mL 
fluorescamine in acetonitrile were added. This was vortexed for 1 min before 100 µl of 
the resultant fluorescent solution was injected onto a Supelco LC-SI C18 column (25 
cm x 4.6 mm, 5 µm, Supelco, Bellefonte, PA, USA). Samples and standards were 
analyzed on a Shimadzu Prominence HPLC system (Shimadzu, Columbia, MD, USA).  
 
2.3.8 Delineation of MDI and TDI specific binding sites on Hb 
Trypsin digestion of hemoglobin samples 
MDI and TDI conjugation sites of Hb were analyzed by ultra-performance liquid 
chromatography quadrupole time-of-flight mass spectrometry (UPLC–qTOF MS). In 
preparation for mass spec analysis, 200 µl aliquots of MDI–Hb and TDI-Hb samples 
were treated with tributylphosphine for 30 min at RT to reduce the disulfide bonds. The 
samples were alkylated with iodoacetamide for 1 h at room temperature. Alkylation was 
quenched by further addition of tributylphosphine for 15 min at room temperature. 
Porcine trypsin in 25 mM NH4HCO3 was then added at a 40:1 (protein/trypsin) ratio. 
Samples were incubated overnight at 37⁰ C. 
 
Ultra Performance Liquid Chromatography (UPLC) 
Tryptic peptides of Hb, TDI-Hb and MDI–Hb were separated on a Waters 
nanoACQUITY UPLC system (Waters, Milford, MA, USA). Aliquots (1 µl) of the 
digest mixture were injected and trapped/desalted on a 5-µm Symmetry C18 trapping 
column (180 µm x 20 mm) with 99.5/0.5 A/B (A: 0.1% formic acid; B: 0.1% formic 
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acid in acetonitrile) at a flow rate of 15 µl/min for 1 min. Separation was performed on 
a 1.7-µm BEH130 C18 analytical column (100 µm  x 100 mm) using gradient elution at 
a flow rate of 400 nl/min and a gradient of 99:1 to 60:40 A/B over 90 min. 
 
MS/MS of Hb peptides 
The eluent from the UPLC system was directed to the nanoelectrospray source of a 
Waters SYNAPT MS qTOF mass spectrometer. Positive ion nanoelectrospray was 
performed using 10 µm Pico-Tip (Waters) emitters held at a potential of +3.5 kV. The 
cone voltage was held constant at +40 V for all experiments. Dry nitrogen desolvation 
gas was supplied to the instrument via a nitrogen generator (NitroFlowLab, Parker 
Hannifin, Haverhill, MA, USA). [Glu]1 Fibrinopeptide B (100 fmol/µl in 75:25 A/B) 
was supplied to an orthogonal reference probe, and the [M+2H]2+ ion (m/z 785.84265u) 
was measured as an external calibrant at 30-s intervals. Ultra-high purity (UHP) argon 
was used as collision gas. Spectra were acquired in an ‘‘MSe’’ fashion58. Alternating 1 
sec mass spectra were acquired. The collision energy was set to 6 eV (1 sec low energy 
scan) and a 15- to 30-eV ramp (1 sec high energy scan). 
 
Data analysis for MDI binding sites on Hb 
Data were analyzed with BioPharmaLynx version 1.2 (Waters), a software program for 
analysis of peptide mass maps and identification of sites of modification on known 
protein sequences. Default peptide mass map analysis criteria of 30 ppm mass error in 
both low- and high-collision energy mode were specified. Trypsin was specified as the 
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digestion enzyme, and two missed cleavages were allowed. Identification of an 
isocyanate binding site proceeded via a rigorous procedure that involved the following 
steps: (i) observing a potential peptide–dNCO conjugation product with less than 30 
ppm m/Dm mass error in the analyte peptide mass map, (ii) comparing analyte and 
control peptide mass map from unmodified Hb showing that observed m/z and 
chromatographic retention time are unique to analyte, and (iii) observing MS/MS data 
containing bn- and yn-type ions consistent with the assigned sequence and modifier.  
 
2.3.9 Identification of MDI bound proteins 
SDS gel electrophoresis of the cytoplasm and membrane fractions were run and protein 
bands with detectable MDA were excised. Trypsin digestion was performed on the 
resultant proteins and the peptides analyzed by mass spectrometry to identify the 
proteins in the gel bands as described previously. 
 
2.3.10 Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) 
dNCO-protein gels 
For denaturing gels, proteins and dNCO–protein conjugates were mixed with 950 µl of 
Laemmli sample buffer and 50 µl of 2- mercaptoethanol. Sodium dodecyl sulfate (SDS) 
acrylamide gels (8 % and 12 %) were cast. Precast gradient gels (4–20%) were obtained 
from Bio-Rad (Hercules, CA, USA). Samples were run on 8 %, 12 %, and 4 %-20% 
gradient polyacrylamide gels. Following electrophoretic separation of proteins, the gels 
were stained with imperial protein stain (Pierce, Rockford, IL, USA) and destained with 
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water. Unmodified protein and Bio-Rad prestained molecular weight markers were used 
for relative molecular weight determination. For native gels, unmodified protein and 
dNCO–protein samples were mixed with native sample buffer from Bio-Rad and run on 
8 % native gels in parallel with unstained protein markers from Life Technologies 
(Carlsbad, CA, USA). Gels were stained and destained as described previously59. 
 
2.3.11 Enzyme-linked immunosorbent (ELISA) assays 
Immunoassay for percentage of number of HSA conjugated. 
Binding of a murine IgM 15D4 mAb to MDI-conjugated HSA was analyzed using a 
sandwich ELISA60,61. Here, 96-well plates (Corning, Corning, NY, USA) were coated 
with 4 µg/ml Affini-Pure goat anti-mouse IgM and µ chain-specific IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) overnight at 4⁰ C. After 
washing three times with PBST (PBS and Tween 20), wells were incubated on a shaker 
for 1 h with 2 µg/ml 15D4 mAb at room temperature. The plates were then blocked 
with 3% skim milk/PBS–Tween 20 (SMPBST) for 1 h at 37⁰ C. Duplicate MDI–HSA 
conjugates were then added to the blocked plates at a concentration of 25 µg/ml and 
incubated for 1 h at 37⁰ C. Plates were then washed three times with PBST and 
incubated for 1 h at 37⁰ C with biotin-conjugated affinity-purified rabbit anti-HSA 
(Rockland, Gilbertsville, PA, USA) diluted 1:5000 (v/v) in SMPBST. The plates were 
then washed three times with PBST and incubated for 1 h at 37⁰ C with alkaline 
phosphatase-conjugated streptavidin (Jackson Immuno- Research Laboratories) diluted 
1:5000 (v/v) in SMPBST. Following incubation, the plates were washed with PBST and 
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binding of the 15D4 mAb to the conjugates was visualized using 0.5 mg/mL p-
nitrophenyl phosphate (Sigma–Aldrich) in alkaline phosphatase substrate. The optical 
density was determined at 405 nm after 30 min. 
 
ELISA for TDI-HSA and TDI-Hb 
Binding of an IgG, 60G2 monoclonal antibody (mAb) to TDI-conjugated HSA and Hb 
was analyzed using an indirect enzyme-linked immunosorbent assay (ELISA)61-63.  96-
well plates (Corning, Corning, NY, USA) were coated with TDI-protein conjugates 
overnight at 4⁰ C. After washing three times with PBST (PBS and Tween 20), wells 
were incubated on a shaker for 1 h with two µg/ml 60G2 mAb at RT. The plates were 
then blocked with 3% skim milk/PBS–Tween 20 (SMPBST) for 1 h at 37⁰ C. Plates 
were then washed three times with PBST and incubated for 1 h at 37⁰ C with alkaline 
phosphatase conjugated affini-Pure goat, anti-mouse IgG(H+L) (Promega, Cat # S3721 
USA) diluted 1:5000 (v/v) in SMPBST. Following incubation, the plates were washed 3 
times with PBST and binding of the 60G2 mAb to the conjugates was visualized using 
0.5 mg/ml p-nitrophenyl phosphate (Sigma–Aldrich) in alkaline phosphatase substrate. 
The optical density was determined at 405 nm after 30 min. 
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                                                     CHAPTER 3 
               DEVELOPMENT OF AN HPLC METHOD FOR QUANTIFICATION  
                         OF DIISOCYANATES CONJUGATION TO HSA AND Hb. 
 
3.1 INTRODUCTION 
Protein haptenation by dNCOs such as MDI, TDI and HDI is thought to be an 
important step in the development of diisocyanate-specific allergic sensitization. The 
fate of the dNCO in the body and the ultimate protein adduct responsible for 
immunological sensitization currently remain unknown32. Apart from directly reacting 
with proteins at the site of exposure, diisocyanates can react with glutathione or 
protein thiols, forming labile thiocarbamate adducts that may possibly be transported 
to sites distal to the site of exposure. It is not known whether the antigenicity of 
proteins adducted by isocyanates regenerated from thiocarbamates is different from 
that via direct haptenation. Diisocyanate-conjugated proteins are used to screen for 
dNCO-specific antibodies in workers’ sera and the assay is commonly used as a tool 
in dNCO asthma diagnosis, however, the assay has been reported to have poor 
sensitivity in confirmed diisocyanate-asthma cases64. Diisocyanate-haptenated 
albumins used for the screening of dNCO-specific antibodies in workers’ sera are 
often poorly characterized. Recently, the need to develop standardized immunoassays 
using a consistent, well-characterized dNCO-haptenated protein to screen for the 
presence of diisocyanate-specific IgE and IgG from workers’ sera has been recognized 
and emphasized65,66. Synthetic methods have been reported for amino acid conjugation 
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using thiocarbamates67, which may possibly find utility in haptenation of whole 
proteins for specific antibody detection.  
 
Isocyanates can react with the following amino acids under physiological conditions: 
the α-amino group of all N-terminal amino acids, the sulfhydryl group of cysteine, the 
hydroxyl groups of tyrosine and especially the ε-amino group of lysine and the 
imidazole ring of histidine68,69. Figure 3.1 shows the structures of the four amino acids 
(excluding those where the N-terminal has been reported bound) that have been 
observed to react with diisocyanates. Isocyanate-specific adducts with the N-terminal 
valine of hemoglobin with MDI have been quantified in rats70. Sepai et. al. found 
hemoglobin adducts correlated with the administered dose of MDI71 while Sabbioni et. 
al. demonstrated that MDA also binds to hemoglobin (through a metabolic 
intermediate) 72. 
 
 
 
 
Figure 3.1: Structures of the amino acids that have been found to react with 
isocyanates. 
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There are several HPLC and GC mass spectrometry methods that have been developed 
and used to characterize dNCO-protein conjugates for biomonitoring of dNCO 
exposure 73,74. The TNBS assay has also been used for characterization of dNCO-
protein conjugates and results have often been over-interpreted75. Gel electrophoresis 
and Western blot analyses provide more qualitative assessment of the dNCO 
conjugates, but are generally of poor resolution and at best can be semi-quantitative 
with respect to degree of haptenation.   
 
In light of these limitations, it was important to develop a sensitive and simple method 
of determining dNCO binding to proteins. The method would be useful for 
characterization of dNCO conjugation to proteins. 
 
3.2. The HPLC method. 
The HPLC system used in this study was a reversed phase with the C-18 R-group of 
the siloxane coating. 
 
3.2.1 Hydrolysis 
The HPLC method is based on the hydrolysis of dNCO-protein conjugates under high 
acid concentrations at elevated temperature. This generates a complex mixture of the 
dNCO hydrolysis products [methylene dianiline (MDA), toluene diamine (TDA) and 
hexamethylene diamine (HDA)], amino acids and several hydrolysis products from 
protein(s). Figure 3.2 below is a simplified scheme of the hydrolysis of an MDI-
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protein conjugate with the protein conjugated on the lysine residue to generate MDA 
and amino acids.  
 
Figure 3.2: The hydrolysis of MDI-protein conjugates in acid and high temperature to 
give MDA 
 
3.2.2 Extraction 
The dNCO diamine hydrolysis product is selectively extracted from the complex 
hydrolysis mixture. After hydrolysis, the diamine hydrolysis product in acid is more 
soluble in aqueous media. Addition of saturated sodium hydroxide deprotonates the 
diamine, making it less soluble in aqueous environments. Subsequent addition of a 
water immiscible organic solvent such as dichloromethane or ethyl acetate results in 
preferential partitioning of the diamine into the organic solvent thus separating the 
diamine from potential interfering substances. 
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3.2.3 Derivatization 
The diamines from the acid hydrolysis of diisocyanate-protein conjugates are not 
conventional fluorophores but can be derivatized to highly fluorescent complexes. 
Fluorescamine was used in this particular work to derivatize the diamine hydrolysis 
products. Fluorescamine is a reagent for the detection of primary amines in the 
picomole range76. Its reaction with amines is almost instantaneous at room 
temperature in aqueous media. The products are highly fluorescent, whereas the 
reagent and its degradation products are non-fluorescent77. The reaction of a primary 
amine with fluorescamine is shown in Figure 3.3 below. 
 
Figure 3.3: The reaction of a primary amine with fluorescamine to form the 
fluorescent complex 
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3.3. RESULTS AND DISCUSSION.  
3.3.1. Optimization of the derivatization reaction 
The diamine-fluorescamine derivatization reaction was studied under different pH 
conditions, in different buffer systems, and in different proportions of acetonitrile to 
the buffer system. Fluorescence intensity was measured using a conventional 
flourometer. Toker SE et al78 reported an HPLC method with fluorescence detection in 
which they performed the fluorescamine derivatization of memantine extracted from 
human plasma. The memantine residue was derivatized by reacting with 320 molar 
excess fluorescamine in 500 mL of borate buffer (pH 8.5), 250 mL of fluorescamine 
reagent solution and 250 mL of acetonitrile. Although memantine has a single primary 
amine group, the conditions they employed were the basis for this optimization 
process.  
3.3.2. Determination of the optimum solvent system for derivatization 
The solvent system that produced the best fluorescence was evaluated by derivatizing 
MDA in different buffers with different proportions of buffer: acetonitrile and at 
different pHs. Table 3.1 below shows the fluorescence intensities obtained when 1000 
ng/ml MDA was derivatized in 0.16 M boric acid at pH 9.6 at different ratios of 
acetonitrile to buffer. The highest fluorescence intensity was obtained when 
derivatization was performed in a 50% acetonitrile-buffer mixture. Table 3.2 shows 
fluorescence intensities obtained when the same experiment was performed in 
saturated borate buffer at pH 8.45 at different ratios of acetonitrile: buffer. In saturated 
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borate buffer, the most intense fluorescence was observed at 66.7% acetonitrile: 
buffer. 
Table 3.1: Fluorescence results obtained with 0.16M boric acid (sodium) buffer 
solution at pH 9.6 
Derivatizing solution( % 
ACN in Boric acid buffer) 
Fluorescence Intensity with 
1000 ng/ml MDA* 
No MDA*(Blank) 
50% 435.946 158.195 
66.7% 272.747 158.195 
80% 280.544 158.195 
87% 287.509 158.195 
100% 276.352 158.195 
*– measurements performed on a flourometer without HPLC separation 
Table 3.2: Fluorescence results obtained with saturated borate buffer pH 8.45 
Derivatizing solution ( % 
ACN in Borate Buffer Added) 
Fluorescence Intensity 
with 1000 ng/ml MDA* 
No 
MDA*(Blank) 
50% 491.236 156.618 
66.7% 520.225 156.618 
80% 277.355 156.618 
87% 280.663 156.618 
100% 264.213 156.618 
*– measurements performed on a flourometer without HPLC separation. 
Comparison of the optimum fluorescence intensities for the two buffers. Saturated 
borate buffer had better fluorescence intensities at both 50 % and 66.7 % acetonitrile: 
buffer compared to 0.16 M boric acid. For saturated borate buffer alone, the best 
fluorescence intensity was obtained at 66.7 % acetonitrile: buffer. It was therefore 
determined that the optimal conditions were to derivatize MDA in 66.7 % acetonitrile: 
saturated borate buffer at pH 8.45 with 320-fold molar excess fluorescamine. 
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3.3.3. HPLC analysis of the derivatized MDA 
After optimizing the derivatization reaction, MDA was dissolved in 0.5% H2SO4 and 
derivatized as described previously. The resultant fluorescent complex was run on the 
HPLC measured in the fluorometer at an excitation λ=410 nm and emission λ=510 nm. 
The following parameters were used on the HPLC to run the MDA standards. 
Parameters 
1. Table 3.3: Gradient elution 
Time Module Action ACN Value (%) 
0.01 Controller Start  
0.02 Pumps Pump B conc 10.0 
13.00 Pumps Pump B conc 50.0 
18.00 Pumps Pump B conc 50.0 
19.00 Pumps Pump B conc 10.0 
20.00 Controller Stop  
NB: Pump B is acetonitrile and pump A is water. 
2. Excitation wavelength: 410 nm, Emission wavelength: 510 nm 
3. Flow rate 1 mL/min 
4. Column C18, 25 cm x 4.4 mm, 5 µm particle size with guard column. 
 
Figure 3.4 is an overlay of  derivatized MDA chromatograms from 1-100 ng/ml. A 
negative solvent control that had no MDA was also derivatized to evaluate the extent 
of background fluorescence. 
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Figure 3.4: MDA chromatograms from HPLC analysis. The retention time for the 
MDA peak was 18.9 minutes. 
 
The MDA peak size increased in a dose-dependent manner with increasing 
concentration of MDA. Figure 3.5 was obtained by blowing out the region from 17 to 
20 minutes to clearly visualize the MDA peak. The peak observed at 18.36 minutes is 
not due to MDA as this peak was present in the negative control and not MDA dose-
dependent. This peak could be due to impurities in the MDA or the fluorescamine. 
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Figure 3.5: MDA chromatograms from HPLC analysis from 17-20 minutes. The 
retention time for the MDA peak was 18.9 minutes. 
 
3.3.4. Extending the derivatization to TDA and HDA  
The derivatization reaction was applied to 2, 4-TDA and HDA to evaluate the utility 
of the method to other di isocyanates. 2,4-TDA, HDA standards were derivatized as 
described previously, and the resultant fluorescent complexes analyzed by HPLC. 
TDA had a retention time of 16.7 min and HDA had a retention time of 14.2 min.  
3.3.5. Direct derivatization calibration curves 
To evaluate the capability of the method for quantification of MDA, TDA and HDA, 
different concentrations of these standards were prepared in 0.5% H2SO4, derivatized 
as previously described and analyzed by HPLC. The diamine-fluorescamine peaks 
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were integrated using the EZstart software and the peak area was plotted against the 
diamine concentration. 
Figure 3.6 below is a calibration curve obtained when different concentrations of 
MDA were analyzed by HPLC. There is a strong linear correlation between the peak 
area and the MDA standard concentration with an r-square value of 0.9986. The limit 
of detection was 1 ng/mL MDA with an injection volume of 100 µL. 
 
Figure 3.6: Calibration curve obtained from the direct derivatization of MDA with 
fluorescamine 
 
When the same experiment was performed with 2, 4-TDA and HDA, the correlations 
were good with correlation coefficients of 0.9947 and 0.9992 for 2, 4-TDA and HDA 
respectively. It is therefore possible to quantify the amount of MDA, 2, 4-TDA or 
HDA in a sample using this HPLC method. 
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3.3.6. Optimization of the extraction 
 
After hydrolysis of the diisocyanate-protein conjugate, the diamine hydrolysis product 
was selectively extracted prior to derivatization. Toluene, dichloromethane, and ethyl 
acetate extraction solvents were compared. MDA was spiked into 0.5mg/ml of HSA 
and Hb solutions, acid hydrolyzed, alkalinized, and extracted using the three solvents. 
No MDA was detected when toluene was used for extraction. Solubility checks 
indicated that MDA is barely soluble in toluene making toluene a poor choice for 
extraction of MDA. Dichloromethane (DCM) and ethyl acetate (EA) were therefore 
employed for extraction of MDA, 2, 4-TDA and HDA and extraction efficiencies of 
the two solvents were tested by using each solvent to extract a 100ng/ml MDA, 2, 4-
TDA and HDA. Table 3.5 shows the extraction efficiencies of the two solvents 
calculated by dividing the peak area of 100 ng/ml MDA, 2,4-TDA and HDA extracted 
using DCM and EA by the peak area of directly derivatized 100 ng/ml MDA, 2, 4-
TDA and HDA. Table 3.6 shows solvents that were chosen for extraction of each 
diamine based on superior extraction efficiencies. 
Table 3.4: Extraction efficiencies obtained for DCM and EA 
 
Solvent Ext efficiency (%) 
for MDA 
Ext efficiency (%) 
 for TDA 
Ext efficiency (%) 
 for HDA 
DCM 1 36.2 ± 17.0 (s.d.) 97.4 ± 3.2 (s.d.) 95.7 ± 3.9 (s.d.) 
EA     1 96.2 ± 4.3 (s.d.) 88.3 ± 4.8 (s.d.) 89.2 ± 4.5 (s.d.) 
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Table 3.5: Extraction solvents chosen for each diamine 
Diamine Solvent with best extraction efficiency 
MDA Ethyl acetate 
2,4-TDA Dichloromethane 
HDA Dichloromethane 
 
3.3.7. Back extraction. 
For most methods reported in literature, the MDA, TDA or HDA organic extraction 
solvent was dried completely under nitrogen and the resultant residue reconstituted 
into an aqueous solvent and derivatized79. Evaporation under nitrogen of ethyl acetate 
to dryness and subsequent reconstitution into 0.5% H2SO4 produced significant and 
inconsistent loss of MDA. However, partial evaporation to reduce the volume of ethyl 
acetate and subsequent back extraction into 400µL of 0.5% H2SO4 resulted in higher 
recoveries of MDA and precise results among replicates. The same experiment was 
performed with 2, 4-TDA and HDA and back extraction into 0.5% H2SO4 also 
produced higher recoveries. 
3.3.8. Extracted calibration curve. 
Different concentrations of MDA, 2, 4-TDA and HDA were spiked into 0.5 mg/mL 
HSA  and Hb and hydrolyzed for 16 hr at 100 ⁰C. The diamines were extracted as 
previously described in section 2.3.6, derivatized and analyzed by HPLC. Human 
serum albumin and hemoglobin were used to evaluate effect of proteins on extraction 
efficiency. Figures 3.7 show a calibration curve obtained when MDA was spiked in 
0.5mg/ml Hb. The same results were obtained when the diamine were spiked into 
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HSA (data not shown). Similar calibration curves were also obtained with 2,4-TDA 
and HDA. 
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Figure 3.7: Calibration curve obtained when MDA was spiked in 0.5 mg/ml Hb, 
extracted and derivatized with fluorescamine 
 
3.4. DISCUSSION AND CONCLUSION 
There are several methods that have been used to characterize dNCO–protein 
conjugates in association with dNCO-specific antibody detection immunoassays and 
also for biomonitoring assays of dNCO exposure58,80. Measurement of total 
conjugated and free dNCO hydrolysis products from urine and plasma, such as MDA, 
analyzed following derivatization by gas chromatography (GC–MS) has been 
extensively employed as a bio monitoring tool for dNCO exposure 81. These methods 
are based on determination of MDA after strong acid or base hydrolysis of MDI–
protein adducts similar to that employed in the current study. Although measurement 
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of the diamine hydrolysis product has been used for biomonitoring, only one study has 
reportedly applied this approach to characterize in vitro prepared HSA conjugates82.  
Several solvents used for the extraction of diamines derived from dNCO hydrolysis 
are commercially available. These include toluene, dichloromethane, and ethyl acetate 
74,83. Toluene is the most commonly extraction solvent reported for both TDI derived 
TDA and MDI derived MDA; however, MDA has poor solubility in toluene. Based on 
extraction efficiencies, ethyl acetate was chosen as the extraction solvent for 
extraction of MDA and dichloromethane for extraction of both 2, 4-TDA and HDA. 
Loss of MDA was observed on complete solvent evaporation under nitrogen but 
partial evaporation of ethyl acetate with subsequent back extraction into 0.5% H2SO4 
produced high, consistent recoveries and was used to extract the diamine from ethyl 
acetate into an aqueous solvent prior to derivatization.  
This HPLC method based on fluorescence detection is applicable for absolute 
quantification of diisocyanate conjugation to proteins by quantifying the diisocyanate 
hydrolysis product following conjugate hydrolysis. This method is inexpensive, 
simple, and sensitive (limit of detection [LOD] = 1 ng/ml). Mass spectral methods 
incorporate an isotopic internal standard that may increase accuracy, especially where 
matrix effects may alter extraction efficiency. However, the external standard 
methodology used for quantification of laboratory haptenated proteins where there is a 
uniform matrix provides sufficient accuracy for quantification of mass of dNCO-
protein conjugated.  
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                                               CHAPTER 4 
CHARACTERIZATION OF METHYLENE DIPHENYL DIISOCYANATE 
CONJUGATED HUMAN SERUM ALBUMIN AND HEMOGLOBIN 
 
4.1 INTRODUCTION 
Diagnosis of dNCO-induced OA remains confounded by methodological limitations 
84. Immunoassay standardization is critical for optimization of immunoassays used to 
detect diisocyanate specific antibodies in workers’ sera as well as comparison of 
results across studies 85. A number of factors that may affect results from these 
immunoassays include the dNCO used, the carrier protein employed, dNCO–protein 
reaction conditions, and post-reaction processing of the haptenated protein. The 
variability of results obtained in these immunoassays may also be due in part to a lack 
of standardization in conjugate preparation and characterization. 
HSA is the most common carrier protein used for dNCO antibody immunoassays 80 
due to its prevalence in plasma to form MDI adducts86. Other molecules, such as 
keratin 18 , tubulin 87, and the peptide, glutathione 88 have been reported to be 
modified by dNCO exposure. Hemoglobin–MDI haptenation occurs in vivo following 
MDI exposure. Sabbioni and coworkers70 reported MDI binding to the N-terminal 
valine of Hb in MDI exposed rats and proposed Hb–MDI as a biological marker of 
MDI exposure. The same authors also found the N-terminal adduct with valine in 
globin of a TDI-exposed worker and in two women with polyurethane-covered breast 
implants 89. The immunogenicity of adducted proteins that have been identified other 
than albumin has not been tested; however, the fact that haptenated keratin and tubulin 
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were identified immunochemically suggests that multiple haptenated protein species 
formed following exposure may be antigens. Due to the lack of characterization of 
protein–dNCO adducts, antibody reactivity toward other endogenous haptenated 
proteins may be overlooked using conventional detection approaches. Other proteins 
assessed as carrier proteins for dNCOs, however, have not been as effective at 
detecting dNCO-specific antibody in the blood of exposed workers. It is not known 
whether this is due to varying degrees of dNCO adduction to different proteins or 
antibody recognition. Characterization of different dNCO–protein conjugates, 
therefore, is important to further our understanding of dNCO haptenation and 
adduction.  
Although MDI accounts for almost 60 % of the global market of dNCO worldwide, 
most of the published biomedical dNCO research studies have used toluene 
diisocyanate (TDI), possibly because of MDI’s lower vapor pressure and lower 
reactivity. Its lower volatility makes respiratory exposure less likely and harder to 
generate into the air for animal studies. There was also a switch about 15 years ago 
from TDI use to MDI use with respect to industrial applications. This could also 
explain why there are not as many research studies reported on MDI. 
Our previous research has been directed towards delineating the concentration-
dependent increase in specific dNCOs such as toluene diisocyanate (TDI) binding sites 
on HSA90. In these studies, the predominant TDI binding sites on HSA were lysine 
residues, although binding to the N-terminal arginine and to glutamine were also 
observed. In another study performed in our laboratory 91, MDI was shown to be 
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bound to the same sites as TDI, but overall the reactivity was reduced. In this study, 
MDI–HSA conjugates were characterized with the aim of developing a standardized 
approach for screening for IgE- and IgG-specific antibodies. MDI reactivity toward 
Hb was also examined and compared with HSA because dNCO-adducted hemoglobin 
has been measured from the blood of exposed workers and used as a biological marker 
of dNCO exposure 92.  
Wong and coworkers 93 reported that acrylonitrile- adducted Hb was antigenic. In 
another study, Pien and coworkers 94 found that rats exposed to the respiratory 
allergen and inducer of late respiratory systemic syndrome, trimellitic anhydride 
(TMA), by inhalation produced IgG that recognized both TMA-haptenated albumin 
and Hb. They demonstrated, through cross-inhibition studies, that TMA–albumin and 
TMA–Hb share antigenic determinants. Collectively, these studies suggest that 
haptenated hemoglobin can be antigenic.  
These experiments sought to (a) use the HPLC method developed to quantify amount 
of MDI conjugation to both HSA and Hb, (b)  evaluate other established techniques 
used to characterize MDI conjugates that are formed with different proteins and (c) 
suggest a set of methods and techniques that can be used to characterize conjugates 
that are used for detection of MDI specific antibodies in workers’ sera.  
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4.2 RESULTS AND DISCUSSION 
4.2.1 Mapping the binding sites of MDI on Hb 
Hb was reacted in vitro (PBS, pH 7.4) to MDI at MDI/Hb molar ratios of 1:1 to 40:1. 
The conjugates produced were digested with trypsin, and resultant peptides were 
analyzed by UPLC–MS/MS to determine MDI binding sites. Examination of the 
tandem mass spectra of the tryptic peptides allowed assignment of conjugation sites on 
Hb as described by Hettick et al95. Fig. 4.1 is a tandem mass spectrum of the b-subunit 
of Hb tryptic fragment 1 to 17 conjugated to MDI on the N-terminal valine. The 
conjugated peptide has a mass of 2098.07, which is in agreement with the theoretical 
mass of the fragment. The b*2 and b*7 ions were conjugated to MDI, appearing 200 u 
higher in mass than the theoretical b2 and b7 ions, indicating that MDI is covalently 
bound to the N-terminal valine at position 1. On the other hand, yn-type ions, y2 to y14, 
all appear at the correct theoretical masses, again further confirming that MDI is 
bound to the N-terminal valine. Polymerization was observed on Lys66 at a 10:1 
MDI/Hb molar conjugation ratio and above.  
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Figure 4.1: Tandem mass spectrum of hemoglobin subunit β fragment 1-17 
conjugated to MDI on the N-terminal valine residue. 
 
Table 4.1 shows the concentration-dependent specific binding sites identified for MDI 
on Hb when MDI was added at molar ratios from 1:1 to 40:1 MDI/Hb. Eight binding 
sites were identified at the highest concentration of MDI used, including the N 
terminal amine of valine on both the alpha and beta chains. MDI bound to two lysines 
on the alpha chain and four additional lysines on the beta chain. The two N-terminal 
valines of the alpha and beta chains, as well as Lys66 on the beta chain, were observed 
to bind at the lowest conjugation ratio of 1:1 MDI/Hb. Increasing MDI concentrations 
increased the number of sites bound to a maximum of eight. All eight binding sites 
were conjugated at a 10:1 molar ratio. Increasing the concentration to 40:1 did not 
increase the number of different amino acids bound. 
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Table 4.1: MDI Hemoglobin conjugation sites 
 MDI:Hb Conjugation Ratios 
Binding Site 1:1  5:1 10:1 40:1 
Alpha subunit     
Val 1 x x x x 
Lys 7  x x x 
Lys 40  x x x 
Beta subunit     
Val 1 x x x x 
Lys 8   x x 
Lys 61   x x 
Lys 65   x x 
Lys 66 x x x x 
 
In contrast, MDI conjugates five different HSA lysines at 1:1 MDI/HSA91. 
Conjugation to the N-terminal Asp in HSA was not observed until the MDI 
concentration was raised to 5:1 MDI/HSA and two glutamine sites were bound at the 
higher conjugation ratios 91. In addition, the number of different amino acid binding 
sites increased through the entire MDI concentration range, with 20 different binding 
sites conjugated at 40:1 MDI/HSA. Table 4.2 compares the number of observed 
binding sites for Hb and HSA. HSA has more lysine binding sites accessible for MDI 
binding compared with Hb through the entire MDI concentration range. However, 
relative to the number of potential lysine binding sites in the two proteins, both 
proteins showed relatively equivalent percentage binding, where the percentage 
binding was calculated as the number of observed binding sites divided by the total 
number of potential binding sites (lysines + N-terminal amines), expressed as a 
percentage. 
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Table 4.2: Comparison of MDI binding sites in Hb and HSA 
 Binding sites 
on Hb 
Binding sites on 
HSA 91 
% Binding Hb % Binding 
HSA  
1 :1 MDI: 
Protein 
3 5 13 9 
5 :1 MDI: 
Protein 
5 11 21 19 
10:1 MDI: 
Protein 
8 13 33 22 
40:1 MDI: 
Protein 
8 20 33 34 
Total number 
of potential 
binding sites 
24 59   
 
4.2.2 Quantification of MDI binding in Hb and HSA 
MDI-conjugated HSA and Hb were hydrolyzed under strong acid conditions to obtain 
free MDA. The MDA was extracted and derivatized with fluorescamine and analyzed 
using HPLC with fluorescence detection. Quantification of the number of moles of 
MDI bound to Hb and HSA measured following acid hydrolysis is reported in Table 
4.3. The number of moles of MDI conjugated to both proteins increased with 
increasing concentration of MDI used for conjugation. On a per mole basis, HSA 
bound a greater amount of MDI than Hb and the effect is more pronounced at very 
low concentrations of MDI as almost 18 times more MDI was conjugated to HSA than 
Hb at 1:1 MDI: protein compared to only 2 times more MDI conjugated to HSA than 
Hb at 40:1 MDI: protein. In addition, although the number of different amino acid 
sites did not increase between 10:1 and 40:1 MDI/Hb, the absolute amount of MDI 
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bound increased 3-fold. This may be indicative of an increasing number of specific 
lysines bound as well as increased MDI polymerization onto a single protein site. 
Table 4.3: The molar quantities of MDI bound to HSA and Hb per mole of protein 
obtained 
Sample * Moles MDI 
per mole Hb 
* Moles MDI per 
mole HSA 
Moles MDA 
(HSA)/Moles 
MDA(Hb) 
1:1   MDI: Protein 0.03 ± 0.01 0.59 ± 0.11 17.96 
5:1   MDI: Protein 0.85 ± 0.04 2.73 ± 0.29 3.20 
10:1 MDI: Protein 1.24 ± 0.03 3.93 ± 0.33 3.17 
 40:1 MDI: Protein 3.87 ± 0.12 8.15 ± 0.95 2.10 
 
 
4.2.3 Cross-linking in MDI–HSA- TNBS assay 
The 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS) assay has been widely used as a 
reagent for determining the concentrations of primary amines and degree of 
substitution. Since dNCOs are bi-functional, when one of the isocyanate moiety binds 
to the protein, the other can hydrolyze into a primary amine and be available to react 
with TNBS. In this case, there will be no net loss of protein amine reactivity. Only 
when both isocyanate moieties react with amine groups on proteins would there be a 
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net loss of amine groups in the protein. Thus, loss of amine reactivity toward TNBS is 
indicative of the extent of cross linking not of the absolute degree of substitution. This 
assay will however not distinguish between intra- and intermolecular cross-linking by 
dNCO or polymerized MDI. 
The TNBS assay was therefore used in this study to evaluate the extent of cross 
linking that occurs when MDI conjugates to HSA. Table 4.4 shows a concentration-
dependent loss of available primary amines with increasing MDI concentrations and, 
thus an increase in the amount of dNCO cross-linking of protein residues. 
Approximately 60% of primary amines in HSA are cross-linked at the highest MDI 
concentration. MDI–Hb cross-linking could not be evaluated by TNBS due to spectral 
interference. Use of fluorescamine to assess free amines on MDI-Hb was not 
successful either due to fluorescent quenching by Hb at 510 nm (data not shown). 
Table 4.4: Cross-linking in HSA-MDI evaluated using the TNBS assay 
Sample 
TNBS Abs(as a % of HSA 
control) 
* % cross linking 
in MDI: HSA 
No   MDI 100.00 0.00 ± 0.00 
1:1   MDI: Protein 83.42 16.58 ± 5.21 
5:1   MDI: Protein 75.04 24.96 ± 2.14 
10:1 MDI: Protein 60.29 39.71± 4.51 
40:1 MDI: Protein 42.12 57.88 ± 7.07 
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Figure 4.2 is a plot of the dose-dependent total MDI bound per mole of HSA and the 
approximate number of MDI that are cross-linked obtained by multiplying the percent 
cross-linking from the TNBS assay times the average of 10 TNBS bound per mole 
HSA divided by 2 (1 cross-linked MDI binds 2 amines).  Thus, loss of 57.88% of 
primary amines at 40:1 MDI: HSA X 10 moles TNBS/HSA = 5.8 amines blocked.  
One MDI blocks 2 amines equaling 2.9 MDI cross-linked per mole HSA.  The 
estimate of the number of MDI involved in cross-linking assumes an insignificant 
number of protein residues cross-liked by MDI polymer.  
Number of MDI cross-linked   =        % cross linking X 10 (TNBS bound/mole HSA) 
                                                            2 (Number of amines cross-linked by 1 MDI) 
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Figure 4.2: Dose-dependent total MDI bound per mole of HSA and the approximate 
number of MDI that are cross-linked. 
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4.2.4 Gel electrophoresis: qualitative assessment of crosslinking in MDI–HSA 
and MDI–Hb 
 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) was 
employed to qualitatively examine the extent of binding and cross-linking. Under 
denaturing conditions, intra-molecular cross-linked proteins migrated at a slower rate 
compared with native protein and also prevented complete protein denaturation, 
causing an apparent migration like that of a smaller protein. Figure 4.3 shows an 8% 
SDS–PAGE gel of 0.5 mg/ml HSA reacted to MDI at different molar ratios of 
MDI/HSA. MDI conjugation of HSA at a 1:1 MDI/HSA conjugation ratio (lane 3) 
resulted in 68- and 71-kDa equivalent bands. At 5:1 MDI/HSA (lane 4), the 68-kDa 
HSA band and the 71-kDa band are still observable with reduced resolution. At the 
higher (10:1 and 40:1) MDI/HSA conjugation ratios (lanes 5 and 6, respectively), 
broad bands that migrated like smaller molecules with leading edges of the bands at 
apparent masses of 63 and 53 kDa were observed. In addition, a faint band between 
100 and 150 kDa was also observed in lane 6, presumably due to intermolecular MDI–
HSA cross-linking.  
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Figure 4.3: An 8% denaturing gel of MDI: HSA. Lane 1is the molecular weight 
marker, lane 2 is HSA, lanes 3, 4, 5, and 6 are 1:1, 5:1, 10:1, and 40:1 MDI: HSA 
conjugates respectively. 
 
Native gel electrophoresis of MDI–HSA conjugates was also assessed (Figure 4.4); 
however, higher molecular weight bands 2- to 3-fold the mass of HSA were observed 
in control samples (lane 2) and identified by digestion and UPLC–MS/MS to be HSA. 
These results demonstrated the aggregation of HSA under the assay conditions and 
prevented the observation of potential intramolecular cross-linking. An MDI 
concentration dependent increase in migration of the conjugate band was also 
observed in the MDI–HSA conjugates similar to that observed under denaturing 
conditions, suggestive of intramolecular cross- linking. The faster migration (apparent 
smaller size) may be possibly attributable to exclusion of intramolecular water(s), 
effectively decreasing the size. 
57 
 
 
Figure 4.4: An 8% native gel of MDI: HSA. Lane 1 is the molecular weight marker, 
lane 2 is HSA and lanes 3, 4, 5, and 6 are 1:1, 5:1, 10:1, and 40:1 MDI: HSA 
respectively. 
 
 
Figure 4.5 is a 4% to 20% gradient gel of 0.5 mg/ml Hb reacted to MDI at four 
different mole ratios of MDI/Hb. Denaturation of Hb resulted in the dissociation of the 
alpha and beta subunits that migrated at 15.2 and 15.9 kDa, respectively. Upon MDI 
conjugation, there was emergence of a band at approximately 30 kDa, which is a result 
of two crosslinked subunits. A dark unresolved smear of high-molecular-weight 
compounds also emerged at 45 kDa and above, suggestive of extensive multiple inter-
subunit cross-linking, and the intensity of this band increased with increasing MDI 
concentrations. A downward shift of the 15.2- and 15.9-kDa subunits with increased 
MDI concentrations was also observed, similar to that found with the MDI–HSA 
conjugates. 
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Figure 4.5: denaturing 4% to 20% gradient gel of MDI-Hb. Lane 1 is the molecular 
weight marker, lane 2 is Hb, and lanes 3, 4, 5, and 6 are 1:1, 5:1, 10:1, and 40:1 
MDI: Hb respectively. 
 
4.2.5 ELISA assessment of percentage of albumin molecules conjugated 
An immunoassay was developed using a mAb IgM developed that detects MDI–
HSA96. The MDI mAb was used as the capture antibody in solid phase, and MDI–
HSA conjugates were detected using an alkaline phosphatase-conjugated anti-human 
albumin antibody. In this assay, the amount of HSA with at least one nucleophilic site 
conjugated by MDI (vs. number of MDI bound per albumin molecule) was quantified. 
As shown in Figure 4.6, the ELISA absorbance becomes saturated at a binding ratio of 
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20:1, with no further increase at 40:1. These results demonstrate that all HSA 
molecules are conjugated to at least one MDI at the 20:1 MDI/HSA conjugation ratio. 
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Figure 4.6:  Immunoassay of MDI haptenated HSA.   
4.3. CONCLUSION 
In the current study, MS/MS was used to delineate specific MDI binding sites on Hb 
and 8 binding sites were identified in Hb. Except for the N-terminal valines on both 
the alpha and beta subunits, Lys66 was the only non-terminal binding site that was 
observed at the lowest MDI concentration studied (1:1 MDI/Hb). Although additional 
MDI binding sites were not observed when the binding ratio was increased from 10:1 
to 40:1, the number of moles of MDI bound per mole Hb increased 3-fold.  
Using the TNBS assay, a concentration-dependent increase in the amount of MDI 
cross-linking of HSA was observed with loss of 58% of primary amine reactivity at 
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40:1 MDI/HSA translating to 2.9 moles MDI cross-linked per mole HSA. The 
estimate of the number of MDI cross-linking assumes that an insignificant number of 
protein residues are cross-linked by MDI polymer. Due to spectral interference from 
Hb, crosslinking in MDI–Hb conjugates could not be assessed quantitatively. 
Intermolecular cross-linking was also observed in both MDI haptenated HSA and Hb 
at the higher conjugation ratios using polyacrylamide gel electrophoresis by the 
appearance of bands approximately 2-fold the monomeric protein masses.  
Immunoassays using a recently developed mAb (15D4) specific for MDI-conjugated 
protein can be formatted in a variety of configurations to provide further information 
to develop a standardized antigen for diisocyanate-specific antibody screening. The 
ELISA format employed in the current study uses an anti-MDI–protein IgM as the 
capture antibody and a labeled anti-HSA as the detection antibody and, thus, measures 
the number of albumin with at least one MDI molecule covalently bound. No increase 
in immuno-reactivity was observed at reaction ratios above 20:1 MDI/HSA, 
suggesting that any increase in bound MDI was due to polymerization and reaction to 
additional HSA nucleophilic sites versus reaction to unbound HSA. Direct binding of 
the haptenated HSA to an ELISA plate with measurement of binding by an mAb (data 
not shown) is also an approach that can be used to standardize the antigenicity of the 
haptenated protein. Wisnewski and coworkers 97 reported that maximal MDI-specific 
IgG reactivity of exposed workers’ sera against MDI–HSA in their immunoassay was 
observed at a conjugation ratio of 200 µg MDI/mg HSA (~50:1). It must be noted that 
the HSA concentration reacted to MDI was 10 times greater than that used in the 
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current study, which very possibly altered the final product given the potential for 
greater intermolecular crosslinking and polymerization associated with these higher 
protein and MDI concentrations. 
Multiple methods should be used to fully characterize dNCO–HSA conjugates for use 
in standardized immunoassays for screening dNCO-specific IgE and IgG from 
workers’ sera. These analyses should include (i) measurement of the amount of 
diamine/mole protein following acid hydrolysis, (ii) TNBS measurement of cross-
linking, (iii) denature gel electrophoresis for indication of inter- and intramolecular 
crosslinking, and (iv) use of mAb for antigenicity standardization. Both qualitative and 
quantitative differences in MDI binding were observed between Hb and HSA 
conjugates, suggesting that normalization to conjugation ratio is not sufficient to 
compare antigenicity of different diisocyanate-haptenated proteins.  
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                                                      CHAPTER 5 
COMPARATIVE ANALYSIS OF TOLUENE DIISOCYANATE AND 
HEXAMETHYLENE DIISOCYANATE CONJUGATION TO HUMAN 
SERUM ALBUMIN AND HEMOGLOBIN 
 
5.1 INTRODUCTION 
Toluene diisocyanate (TDI) and hexamethylene diisocyanate (HDI) are widely used in 
the manufacture of polyurethane products and both have been reported to cause 
respiratory sensitization and occupational asthma (OA) in exposed workers98. Once 
allergic sensitization to isocyanates occurs, asthmatic reactions may be triggered by 
exceedingly minute concentrations99,100. Both TDI and HDI are relatively volatile and 
exposure occurs predominantly through inhalation at workplaces17. However, dermal 
exposure has also been reported to cause asthma-like symptoms.  
There are differences in reactivity between aromatic isocyanates and aliphatic 
isocyanates. In a study by Wisnewski et al101 in which albumin was conjugated to TDI 
and HDI by GSH-TDI and GSH-HDI, respectively, the kinetics of GSH-HDI mediated 
albumin carbomylation at neutral pH was substantially slower compared with those of 
GSH-TDI. These researchers also found that GSH-HDI conjugates were more stable 
compared to aromatic isocyanate-GSH conjugates which probably explain the slower 
rate of HDI carbomylation by GSH-HDI. The hydrolysis of aliphatic isocyanates is 
also much slower than aromatic isocyanates. The reactivity of HDI directly conjugated 
to proteins may however confer different kinetics.  
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Diisocyanate-adducted hemoglobin in vivo immunogenicity or antigenicity has not yet 
been evaluated. Wong and coworkers93 reported that acrylonitrile- adducted Hb was 
antigenic. Pien and coworkers102 also found that rats exposed to the respiratory 
allergen and inducer of late respiratory systemic syndrome, trimellitic anhydride 
(TMA), by inhalation produced IgG that recognized both TMA-haptenated albumin 
and Hb. They demonstrated, through cross inhibition studies, that TMA–albumin and 
TMA–Hb share antigenic determinants. Collectively, these studies suggest that 
haptenated hemoglobin can be antigenic. 
Previous work was focused on developing an HPLC method for quantitative 
characterization of dNCO-protein adducts as well as characterization of MDI-HSA 
and MDI-Hb conjugates for immunoassay standardization59. The experiments reported 
herein sought to (i) extend the characterization of the conjugates formed upon reaction 
of TDI and HDI with HSA and Hb to determine the amount of diisocyanate bound, (ii) 
utilize the TNBS assay and SDS gel electrophoresis to evaluate extent of intra- and 
inter-molecular cross linking, (iii) delineate TDI binding sites on Hb and (iv) evaluate 
the antigenicity of TDI and HDI conjugates using a mAb produced in our lab.  
 
5.2 RESULTS AND DISCUSSION 
5.2.1 Mapping TDI binding sites on Hb 
Hb-TDI conjugates were digested with trypsin, and resultant peptides were analyzed 
by UPLC–MS/MS to determine TDI binding sites. Examination of the tandem mass 
64 
 
spectra of the tryptic peptides allowed assignment of conjugation sites on Hb as 
described previously59. Table 5:1 below shows the concentration-dependent specific 
binding sites identified for TDI on Hb. 
Table 5.1 TDI binding sites on Hb at different concentrations of TDI. 
 1:1 5:1 10:1 40:1 
Alpha subunit     
Val 1 x x x x 
Lys 11  x x x 
Lys 16   x x 
Lys 40    x 
Beta subunit     
Val 1 x x x x 
Lys 17   x x 
Lys 144   x x 
Lys 61    x 
 
Eight binding sites were identified at the highest concentration of TDI used, including 
the N-terminal valine on both the alpha and beta chains. TDI bound to three lysines on 
the alpha chain and three additional lysines on the beta chain. Only the two N-terminal 
valines of the alpha and beta chains were bound at the lowest conjugation ratio of 1:1 
TDI:Hb. Increasing TDI concentrations increased the number of sites bound to a 
maximum of eight at 40:1 TDI:Hb. Although there are similarities with MDI binding 
sites previously reported (Table 4.1)59, there are significant differences as well. MDI 
bound two lysines on the alpha chain compared to three for TDI and four lysines on 
the beta chain compared to three for TDI. Only lysine 40 of the alpha subunit and 
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lysine 61 of the beta subunit were bound by both MDI and TDI. Lysines 11 and 16 of 
the alpha subunit and lysines 17 and 144 of the beta subunit were only observed in 
TDI (Table 5.1). On the other hand, lysine 7 of the alpha subunit and lysines 8, 65 and 
66 of the beta subunit were only observed with MDI. Although MDI bound to the two 
N-terminal valines of both the alpha and beta subunits just as TDI, lysine 66 was 
bound by MDI at 1:1 MDI:Hb. This lysine was not bound by TDI even at the highest 
concentration of TDI used. All eight binding sites observed in MDI:Hb were 
conjugated at a 10:1 molar ratio and increasing the concentration to 40:1 did not 
increase the number of different amino acids bound. This is in contrast to TDI:Hb 
were the number of different amino acid binding sites increased throughout the entire 
TDI concentration range, with only six binding sites observed at 10: 1 TDI: Hb. Table 
5:2 below compares the binding sites observed for TDI and MDI on Hb. 
Table 5.2 Comparative analysis of MDI and TDI binding sites on Hb. 
 Alpha subunit Beta subunit 
 MDI:Hb TDI:Hb MDI:Hb TDI:Hb 
1:1 Val 1 Val 1 Val 1, Lys 66 Val 1 
5:1 Val 1, Lys 7, 
Lys 40 
Val 1, Lys 11 Val 1, Lys 66 Val 1 
10:1 Val 1, Lys 7, 
Lys 40 
Val 1, Lys 11, 
Lys 16 
Val 1, Lys 66, 
Lys 8, Lys 61, 
Lys 65 
Val 1, Lys 17, 
Lys 144 
40:1 Val 1, Lys 7, 
Lys 40 
Val 1, Lys 11, 
Lys 16, Lys 
40 
Val 1, Lys 66, 
Lys 8, Lys 61, 
Lys 65 
Val 1, Lys 17, 
Lys 144, Lys 
61 
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The differences in the binding sites between MDI and TDI can give an insight into the 
structural differences in the resultant conjugates, which potentially affects disease 
mechanisms.  
5.2.2 Quantification of TDI and HDI binding on Hb and HSA  
TDI and HDI-conjugated HSA and Hb were hydrolyzed as previously described in 
section 2.3.6 and the resultant TDA and HDA was extracted and derivatized with 
fluorescamine and quantified using HPLC. The number of moles of TDI and HDI 
bound to Hb and HSA is shown in Table 5:3 below.  
Table 5.3: Amount in moles of TDI and HDI conjugated to HSA and Hb. 
Ratio dNCO: 
protein 
dNCO: HSA dNCO: Hb 
 TDI: HSA HDI: HSA TDI: Hb HDI: Hb 
1:1 0.51 ± 0.56 0.04 ± 0.41 0.15 ± 0.15 0.02 ± 0.21 
5:1 2.65 ± 0.23 0.44 ± 0.45 0.57 ± 0.02 0.13 ± 0.23 
10:1 5.06 ± 0.43 0.82 ± 0.36 1.48 ± 0.09 0.32 ± 0.60 
40:1 12.86 ± 0.56 2.79 ± 0.40 4.31 ± 0.06 1.03 ± 0.59 
 
The number of moles of TDI and HDI bound in both HSA and Hb increased with 
increasing concentration of TDI and HDI used. On a per mole basis, HSA was three 
times more reactive to both TDI and HDI than Hb at all dNCO/protein conjugation 
ratios. These results agree with our earlier findings with MDI-HSA and MDI-Hb 
conjugates, where HSA was more reactive to MDI than Hb. This could be a result of 
the structural differences between HSA and Hb. Hemoglobin, with four subunits (two 
alpha and two beta) and the iron containing porphyrin ring, may mask potential 
binding sites thus affecting its reactivity with dNCOs. This contrasts sharply with 
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HSA, a single polypeptide with 585 residues containing 17 pairs of disulfide bridges 
and 1 free cysteine. TDI was five times more reactive to HSA than HDI and 4 times 
more reactive to Hb than HDI. The extent of TDI conjugation to both HSA and Hb 
was similar to our previous results with MDI, both of which are aromatic 
isocyanates59. TDI is reported to be have a higher rate constant than MDI in their 
reaction with nucleophiles such as alcohols. 
 
5.2.3 Cross-linking in TDI–HSA:TNBS assay 
The extent of cross-linking in TDI-HSA was evaluated using the TNBS assay that 
measures the loss of primary amine reactivity. Table 5.4 shows a concentration-
dependent loss of available primary amines with increasing TDI and HDI 
concentrations and, thus, an increase in the amount of dNCO cross-linking.  
Table 5.4 Cross-linking in TDI/HDI-HSA using the TNBS assay. 
dNCO: protein 
molar ratio 
Loss of TNBS Amine reactivity (%) 
 MDI: HSA HDI: HSA 2,4-TDI: HSA 
Negative control 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
1:1 16.58 ± 5.21 25.46 ± 2.34 18.04 ± 3.98 
5:1 24.96 ± 2.14 30.24 ± 2.89 31.47 ± 3.57 
10:1 39.71± 4.51 32.88 ± 3.14 39.92 ± 4.14 
40:1 57.88 ± 7.07 48.35 ± 3.76 62.42 ± 4. 18 
 
A 62 % loss of primary amine reactivity at 40:1 TDI:HSA and loss of 48% amine 
reactivity at 40:1 HDI:HSA was observed. At lower TDI and HDI concentrations (1:1-
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10:1 TDI/HDI:HSA), the degree of cross-linking was almost the same. However at 
40:1 dNCO:HSA, TDI had a significantly higher degree of cross-linking than HDI. 
5.2.4 Gel electrophoresis: qualitative assessment of conjugation and crosslinking 
in TDI/HDI–HSA and TDI/HDI–Hb. 
Polyacrylamide gel electrophoresis was used to evaluate the extent of binding and 
cross-linking. Figure 5:1 shows an 8% SDS– PAGE gel of 0.5 mg/ml HSA reacted 
with TDI. Conjugation of TDI to HSA at a 1:1 molar ratio (Fig 5:1, lane 3) resulted in 
68- and 71-kDa equivalent bands. This doublet, which was not observed with the HSA 
control, is a result of TDI conjugation, which results in an increase in the molecular 
weight of the HSA. At 5:1 TDI:HSA (Fig 5:1, lane 4), the 68-kDa HSA and the 71-
kDa bands are still observable with reduced resolution. At the higher 10:1 and 40:1 
TDI/HSA conjugation ratios (lanes 5 and 6, respectively), broad bands that migrated 
like smaller molecules with leading edges of the bands at apparent masses of 
approximately 63 and 53 kDa were observed. 
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Figure 5.1: denaturing 8% gel of TDI-HSA. Lane 1 is the molecular weight marker, 
lane 2 is HSA, and lanes 3, 4, 5, and 6 are 1:1, 5:1, 10:1, and 40:1 TDI: HSA 
respectively. 
 
Figure 5:2 is an 8% gel of 0.5 mg/ml Hb reacted with TDI. Denaturation of Hb 
resulted in the dissociation of the alpha and beta subunits that migrated at 15 kDa. A 
dark band and an unresolved smear of high-molecular-weight compounds at 30 kDa 
and above suggests extensive inter-subunit cross-linking, and the intensity of this band 
increased with increasing TDI concentrations. A downward shift of the 15-kDa 
subunits with increased TDI concentrations was also observed, similar to that found 
with the TDI–HSA conjugates.  
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Figure 5.2: denaturing 12% gel of TDI-Hb. Lane 1 is the molecular weight marker, 
lane 2 is Hb, and lanes 3, 4, 5, and 6 are 1:1, 5:1, 10:1, and 40:1 TDI: Hb 
respectively. 
Intermolecular cross-linking was observed in both dNCO-HSA and dNCO-Hb by the 
appearance of bands higher than the molecular weight of the native proteins. 
Intramolecular cross-linking was also evidenced by a dNCO concentration-dependent 
downward shift in the leading edge of the protein band. Extensive intramolecular 
cross-linking increases conjugate mobility, presumably due to inhibition of complete 
denaturation under denaturing conditions and exclusion of intramolecular water under 
native conditions. The same observations were made with HDI-HSA and HDI-Hb 
conjugates (results not shown). 
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5.2.5 ELISA assessment of TDI-HSA /Hb. 
Binding of an IgG, 60G2 monoclonal antibody (mAb) raised against TDI-KLH to 
TDI-conjugated HSA and Hb was analyzed using an indirect enzyme-linked 
immunosorbent assay (ELISA) as described in section 2.3.11103,104. Figure 5:3 below 
is a plot of absorbance readings at 10:1 and 40:1 of TDI conjugated HSA and Hb. As 
expected, reactivity of conjugates to 60G2 was higher at 40:1 TDI-protein than 10:1 in 
both HSA and Hb conjugates. TDI-HSA was almost three times more reactive to 
60G2 than TDI-Hb at both 40:1 and 10:1 TDI-protein. 
Both TDI-HSA and TDI-Hb reacted to the anti-TDI-protein mAb, demonstrating the 
antigenicity of dNCO bound Hb. TDI-Hb reactivity was almost 30% lower than that 
observed for TDI-HSA. This is in agreement with HPLC results where three times the 
amount of TDI bound to HSA than it did to Hb. Hettick et al identified 37 TDI 
binding sites on HSA. In our study, only 8 binding sites were identified on Hb. These 
findings clearly indicate that the observed differences in antigenicity could be a 
function of number of dNCO bound per mole of protein and or availability in sera for 
dNCO conjugation.  
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Figure 5.3:  Immunoassay of TDI haptenated HSA and Hb.   
 
5.3. CONCLUSION 
This is the first time that the specific TDI binding sites on Hb have been reported. 
Although there are similarities with our previous report on MDI binding sites, there 
are also differences between TDI and MDI binding sites. This is also the first time Hb-
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dNCO conjugates were demonstrated to be antigenic. Although their involvement in 
disease development can‘t be inferred from the observed antigenicity, it is important to 
evaluate the antigenicity of potentially endogenously haptenated proteins. Both 
qualitative and quantitative differences in TDI and HDI binding were observed 
between Hb and HSA conjugates. This suggests that the choice of the isocyanate for 
use in immunoassays has to be carefully considered. 
 
 
 
 
 
 
 
 
 
 
                                                            
 
 
 
74 
 
                                                                CHAPTER 6 
EVALUATING THE POTENTIAL FOR AN IgE INDEPENDENT 
MECHANISM THROUGH WHICH DIISOCYANATE ASTHMA DEVELOPS 
6.1 INTRODUCTION 
Although the ultimate immunogenic forms that lead to dNCO asthma are still 
unknown, dNCOs are low molecular weight chemical sensitizers that require 
haptenation to biomolecules in vivo to produce dNCO-specific immune sensitization. 
A number of biomolecules are targets for dNCO conjugation. Epithelial proteins are 
the major targets upon inhalation exposure105,106 whereas skin proteins are targeted 
upon skin exposure and both exposures can lead to OA. Kennedy et al107, using a rat 
model demonstrated that serum albumin is the major target for TDI conjugation in the 
blood.  
The traditional mechanism for development of asthma involves recognition and 
endocytosis of antigens by antigen presenting cells. These cells then digest the 
antigens and associate the resultant peptides with major histocompatibility complex 
molecules (MHC).  The MHC-peptide complex is then expressed on the cell surface 
together with co-stimulatory molecules, a requirement for successful CD4+ T-cell 
(Th0) activation106.  Differentiation of TH0 to TH1 or TH2 subtypes depends on the 
nature of the antigen, cooperating cells, and cytokines. Allergenic antigens plus an 
environment rich in IL-4 from mast cells encourage Th2 phenotype development that 
leads to enhanced production of IL-4, IL-5, IL-3, and GM-CSF with minimal IFN-γ 
production. The Th2 subtype is associated with IgE and eosinophilia and hence 
allergy.  
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Only about 25 % of dNCO asthmatic workers have detectable levels of IgE to dNCO 
HSA conjugates108. Although there is evidence that chemicals that cause respiratory 
sensitization provoke immune responses of the TH2 type, the mechanism of dNCO 
OA may possibly include cell-mediated and mixed reactions109,110. In a study by 
Bottomly et al 111, female BALB/c mice sensitized to HDI developed HDI-specific 
IgG as well as elevated levels of IL-5, IL-13 and IFN- γ on stimulation with HDI-
mouse serum albumin, indicating a mixed TH1/TH2 immune response. Most 
importantly, these investigators observed that the sensitizing dose for antibody 
production was higher than that for airway inflammation and cytokine production. 
This suggests that different mechanisms dominate for the two outcomes. Del prete 112 
and Maestrelli113 demonstrated that the majority of T-cell clones from patients with 
TDI-induced asthma were CD8+ and capable of producing IL-5. David I. Bernstein et 
al114 demonstrated that repeated antigenic stimulation of dNCO asthmatic peripheral 
blood mononuclear cells (PBMC) in culture resulted in synthesis of tumor necrosis 
factor-α (TNF- α), a non-IgE dependent pro-inflammatory cytokine, and monocyte 
chemo-attractant protein-1, but not IL-4 or IL-5.  
THP-1 cells were used in this study as a surrogate for antigen presenting cells and they 
were derived from the peripheral blood of a 1-year-old male with acute monocytic 
leukemia. They are single, round suspension cells with distinct monocytic markers115 
with Fc and C3b receptors and lack surface and cytoplasmic immunoglobulins. THP-1 
cells have advantages in studies over human primary monocytes-macrophages because 
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they have a homogeneous genetic background, which minimizes the degree of 
variability in the cell phenotype116,117.  
The detection of dNCO specific antibodies in only a subset of dNCO asthmatics has 
been attributed to assay limitations and the potential for other non-IgE dependent 
mechanisms. Our previous work has been focused on characterization of dNCO-
protein conjugates that are used in immunoassays for detection of dNCO specific 
antibodies with a view to standardize these immunoassays. We have also evaluated 
conjugates prepared in different conditions to evaluate the effect of preparative 
conditions on the nature of the conjugates. In this work, we hypothesize that MDI, 
apart from reacting with extracellular proteins, can also cross cell membranes intact 
and react with intracellular proteins. This will result is formation of intracellular 
conjugates which can possibly trigger cell mediated immune responses. To test this 
hypothesis, the aims of this work were: (a) to expose THP-1 cells to different 
concentrations of MDI, (b) use the HPLC method to analyze the membrane and 
cytoplasm fractions for MDI conjugation, and (c) identify proteins from MDI-exposed 
THP-1 cells using mass spectrometry. 
6.2 RESULTS AND DISCUSSION 
6.2.1 Quantification of MDI in the cytoplasm 
THP-1 cells were incubated with different concentrations of MDI (dissolved in 
ethylene glycol dimethyl ether) and exposures were performed in Hanks’ balanced 
solution for 4 h at 37 ⁰C and 5 % CO2. After washing three times, the cells were lysed 
using an ultra-sonicator and the cytoplasm fraction was extracted using cytoplasm 
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extraction kits. The cytoplasm fraction was dialyzed against PBS buffer for 18 h to 
remove any MDI/MDA that was not conjugated to proteins. These samples were then 
hydrolyzed, extracted, and analyzed by HPLC as described in sections 2.3.6 and 2.3.7. 
Table 6.1 below shows the moles of MDI from the cytoplasm fraction. 
Table 6.1 Moles of MDI from the cytoplasm fraction of MDI-exposed THP-1 cells 
CYTOPLASM FRACTION OBTAINED USING PROTEIN EXTRACTION 
KITS 
MDI 
concentration 
(µM) 
Viability post 
exposure (%) 
Protein 
conc(mg/ml) 
µM MDI 
Bound 
 
% MDI of dose 
bound  
 
0 80.20±1.23 3.15±0.23 0.00 ± 0.00 0.00 ± 0.00 
5 80.20±3.21 3.33±0.36 0.44 ± 0.06 8.87 ± 0.06 
10 78.67±1.02 2.37±0.28 1.01 ± 0.08 10.13 ± 0.08 
25 80.87±4.92 2.28±0.61 2.56 ± 1.36 10.22 ± 1.36 
50 83.07±2.42 1.67±0.53 4.24 ± 0.03 8.49 ± 0.03 
100 79.40±3.12 1.68±0.49 8.94 ± 1.13 8.94 ± 1.13 
 
These results show that MDI does cross THP-1 cell membranes and react with 
intracellular proteins. The amount of MDI conjugated increased with increasing 
concentration of MDI exposed. The amount of MDI that gets into the cell and 
conjugates to the cytoplasm fraction varied slightly from 8.49 % to 10.22 % of the 
exposure MDI dose. In our previous work with MDI-HSA, the percentage of MDI 
conjugated to HSA varied from 22.75 % to 70 % with the highest percentage of MDI 
conjugation observed at the lowest MDI exposure. MDI exposure over the 4 h 
exposure time did not significantly affect the viability of the THP-1 cells. The amount 
of extracted protein quantified using nano drop absorbance at 280 nm decreased with 
increasing concentration of MDI. Two possible explanations can explain this reduction 
in protein content with increasing concentration of MDI; (i) extensive MDI 
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conjugation may significantly reduce solubility of proteins in the extraction buffers 
used. This phenomenon was observed with MDI conjugated HSA and Hb where the 
conjugates tend to precipitate out of solution with time after conjugation, (ii) MDI-
conjugation may interfere with protein absorbance at 280 nm compromising the 
protein quantification. 
6.2.2. Quantification of MDI in the cell membrane fraction 
The membrane fraction of MDI exposed THP-1 cells consist of the plasma membrane 
and intracellular organelle membranes.  These were extracted using membrane protein 
extraction kits, dialyzed against PBS buffer using 12-14 000 MWCO membranes. The 
dialyzed samples were hydrolyzed, extracted and analyzed for MDI using HPLC as 
described in section 2.3.6 and 2.3.7. Table 6.2 shows the amount of MDI bound to the 
membrane fraction. As expected, the amount of MDI bound to the membrane fraction 
increased with increasing amount of MDI used. MDI binding in the membrane 
fraction was less than that obtained from the cytoplasm fraction. It is also important to 
note that the protein content was significantly lower in the membrane fraction 
compared to the cytoplasm fraction as well.   
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Table 6.2. Moles of MDI from the membrane fraction of MDI-exposed THP-1 cells 
MEMBRANE FRACTION OBTAINED USING PROTEIN EXTRACTION 
KITS 
MDI conc 
(uM) 
Viability post 
exposure (%) 
Protein conc 
(mg/ml) 
uM MDI 
Bound 
% MDI dose 
bound 
0 82.07±0.89 0.22±0.03 0.00±0.00 0.00±0.00 
5 87.55±0.07 0.28±0.02 0.04±0.01 0.84±0.10 
10 89.80±3.25 0.20±0.05 0.06±0.01 0.62±0.11 
25 83.63±4.61 0.19±0.07 0.31±0.03 1.23±0.06 
50 79.87±4.38 0.24±0.03 0.45±0.19 0.90±0.38 
100 78.80±4.52 0.10±0.11 1.14±0.44 1.14±0.45 
 
 
6.2.3 Evaluating the effect of exposure time on the extent of MDI binding 
THP-1 cells were exposed to 100 µM MDI for 30 min, 1 h, 2 h, and 4 h. Cells were 
processed as described in section 7.4 and both the cytoplasm and membrane fractions 
were analyzed for MDI binding. Table 6.3 shows the amount of MDI bound in the 
cytoplasm fraction as a function of time. There is no significant change in MDI 
binding as exposure time is changed from 0.5 to 4 h. The kinetics of MDI entry into 
cells and subsequent binding to the cytoplasm is complete within 30 min. Table 6.4 
shows MDI binding in the membrane fraction. As was observed in the cytoplasm 
fraction, there was no significant change in MDI binding in the membrane fraction 
with time.  
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Table 6.3 Effect of exposure time on MDI binding in the cytoplasm fraction  
CYTOPLASM FRACTION  
MDI (µM) Viab (%) µM MDI 
Bound 
% MDI binding 
30 mins 85.77±1.92 11.43±2.23 11.43±2.23 
1 hour 88.90±1.74 10.68±1.63 10.68±1.63 
2 hours 83.63±1.87 9.21±4.98 9.21±4.98 
4 hours 86.30±1.13 10.74±0.46 10.74±0.46 
 
 
Table 6.4. Effect of exposure time on MDI binding in the membrane fraction 
MEMBRANE FRACTION  
MDI (µM) Viab (%) µM MDI 
Bound 
% MDI binding 
30 min 85.77±1.92 1.04±0.29 1.04±0.29 
1 hour 88.90±1.74 0.97±0.52 0.97±0.52 
2 hours 83.63±1.87 1.01±0.47 1.01±0.47 
4 hours 86.30±1.13 1.04±0.32 1.04±0.32 
 
6.2.4. Control experiments 
Several control experiments were performed to understand the mechanism of entry of 
MDI in the cell as well as to confirm that the MDI that was detected in both the 
membrane and cytoplasm fractions was protein bound and not a result of hydrolyzed 
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MDA that was not sufficiently washed away. The following control experiments were 
therefore performed: 
(i) Co-incubation of THP-1 cells with MDI and cytochalasin D 
To understand the mechanism of entry of MDI into cells, THP-1 cells were incubated 
with cytochalasin D for 1 h and incubated with 50 µM MDI for 4 additional hours. 
Cytochalasin D is a microtubule inhibitor that inhibits active uptake of substances by 
cells.  
(ii) Co-incubation with MDA 
To test the effectiveness of the washing steps to get rid of any residual MDA resulting 
from the hydrolysis of MDI, THP-1 cells were incubated with 50 µM MDA and 
analyzed to see if free (non-protein bound) MDA is detected in the resultant cytoplasm 
or membrane fractions. 
(iii) Co-incubation with ethylene glycol dimethyl ether (EGDE) 
Ethylene glycol dimethyl ether was the solvent used to dissolve the MDI before 
exposure to the THP-1 cells. The effect of the solvent on cell viability was evaluated.  
Tables 6.5 and 6.6 show the amount of MDI detected in the cytoplasm and membrane 
fraction of control exposures described above. As table 6.5 shows, there was no 
difference in the amount of MDI binding in the cytoplasm between THP-1 cells 
exposed to just 50 µM MDI and those co-incubated with 50 µM MDI and 10 µM 
cytochalasin D. This indicates that the entry of MDI into cells is a passive process that 
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does not require energy. There was however a decrease in MDI binding to the 
membrane fraction when THP-1 cells were co-incubated with cytochalasin D. Co-
incubation of THP-1 cells with MDA did not result in detection of MDA in the cell 
fractions. This means the washing steps employed post exposure were sufficient to 
remove any MDA that was not bound to proteins. The EGDE does not significantly 
affect cell viability. 
 
Table 6.5 Amount of MDI detected in the cytoplasm fraction of control exposures 
Cytoplasm fraction from exposure controls 
Sample Viab (%) µM MDI Bound  % MDI binding 
THP-1+10 µM Cytochalasin 
D + 50 µM MDI 
75.22±4.50 4.06±0.62 8.12±1.21 
THP-1+ 50 µM MDI 83.07±2.42 4.24 ± 0.03 8.49 ± 0.03 
THP-1 and 50 µM MDA 80.90±1.23 0.00±0.00 0.00±0.00 
THP-1 and 1% EGDE 89.65±1.56 0.00±0.00 0.00±0.00 
 
Table 6.6 Amount of MDI detected in the membrane fraction of control exposures 
Membrane fraction from exposure controls 
Sample Viab (%) µM MDI Bound  % MDI binding  
THP-1+10 µM Cytochalasin 
D + 50 µM MDI 
75.22±4.50 0.26±0.04 0.52±0.08 
THP-1+50 µM MDI 83.07±2.42 0.45±0.19 0.90±0.38 
THP-1 and 50 µM MDA 80.90±1.23 0.00±0.00 0.00±0.00 
THP-1 and 1 % EGDE 89.65±1.56 0.00±0.00 0.00±0.00 
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6.2.5. Detection of MDI in specific SDS gel bands from MDI exposed THP-1 cells  
An alternative approach to confirm that the MDI detected in the cytoplasm fraction 
was protein bound was employed and involved resolution of proteins from the 
cytoplasm fraction using one-dimensional SDS gel electrophoresis. The resolved 
protein bands were excised, hydrolyzed and the resultant MDA extracted and analyzed 
by HPLC. Figure 6.1 shows an SDS gel obtained with the cytoplasm fraction. There 
are too many protein bands to clearly resolve individual proteins from a one-
dimensional gel, however,  13 bands numbered 1-13 were selected for HPLC analysis 
of  MDA after acid hydrolysis as previously described (Figure 6.1). These bands were 
excised and after analysis, 11 of the 13 bands had detectable levels of MDI. Table 6.7 
shows the amount of MDI that was quantified from the 13 bands excised from the 
cytoplasm fraction. These results further confirm that the MDI that was detected in the 
cytoplasm fraction was protein bound and MDI binding seems to be non-selective 
with the more abundant proteins (darker bands) having the higher amount of MDI 
bound. 40: 1 MDI: HSA was run in parallel as a control and as can be seen three bands 
(a, b, and c) were visible and there were excised and analyzed for MDI as well. As 
expected, band c, which was shifted further down relative to unconjugated HSA as a 
result of extensive MDI conjugation, had a very high amount of MDI. Band b, which 
most likely arises from a combination of MDI binding and extensive intermolecular 
cross-linking, also had a detectable amount of MDI conjugated. 
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Figure 6.1. Resolution of THP-1 Cytoplasm proteins. A 12 % denaturing gel of MDI 
exposed THP-1 cells’ cytoplasm fraction. Lane 1 is the molecular weight marker, lane 
2 is HSA, lanes 3 is 40:1 MDI: HSA, 4 is unconjugated THP-1 cytoplasm and lanes 5-
9 are replicates of the cytoplasm fraction exposed to 100 µM MDI. 
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Table 6.7. MDI quantified from gel bands from the cytoplasm fraction 
Sample MDA conc (ng/ml) 
THP1 1:40 HSA:MDI a 0.00 
THP1 1:40 HSA:MDI b 55.89 
THP1 1:40 HSA:MDI c 107.84 
THP1 Band 1 4.07 
THP1 Band 2 5.61 
THP1 Band 3 5.17 
THP1 Band 4 6.15 
THP1 Band 5 10.77 
THP1 Band 6 7.43 
THP1 Band 7 10.69 
THP1 Band 8 0.00 
THP1 Band 9 16.27 
THP1 Band 10 0.00 
THP1 Band 11 5.51 
THP1 Band 12 7.11 
THP1 Band 13 6.38 
 
6.2.6 Identification of MDI bound proteins from bands with detectable MDI 
The bands from the cytoplasm fraction were also analyzed by proteomic mass 
spectrometry to identify the proteins in each band. This experiment was meant to 
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identify proteins that were present in the gel bands from the cytoplasm of MDI 
exposed THP-1 cells. There is no difference in the protein content between exposed 
and unexposed cells and the protein identification did not detect MDI- bound peptides. 
Table 6.8 is a list of all the proteins that were identified. Because this is a one-
dimensional gel, there are several proteins that co-migrate in each band.  
Table 6.8. The list of proteins identified from the 13 bands excised from the cytoplasm 
fraction 
Protein 
Band 
Proteins identified 
1 Alpha actinin 4, Neutral alpha glucosidase, Ubiquitin like modifier 
activating enzyme 
2 Endoplasmin OS Macaca fascicularis, Heterogeneous nuclear 
ribonucleoprotein, Elongation factor 2, Alpha actinin 1, Transitional 
endoplasmic reticulum ATPase 
3 Heat shock protein HSP 90 beta OS, Heat shock protein HSP 90 alpha 
OS, Calnexin OS, Far upstream element binding protein 2 OS 
4 78 kDa glucose regulated protein OS, Ezrin OS, Heat shock protein HSP 
90 beta, X ray repair cross complementing protein 5 OS  
5 Heat shock cognate 71 kDa protein OS, Moesin OS, Stress 70 protein 
mitochondrial OS, Annexin A6 OS, Aminopeptidase B OS, Adenylyl 
cyclase associated protein 1 OS Pongo abelii, Heat shock protein 75 kDa 
mitochondrial OS, CTP synthase 1 OS, Serum albumin OS Bos taurus  
6 Protein disulfide isomerase OS, Adenylyl cyclase associated protein 1 OS 
Pongo abelii, alreticulin OS Macaca fuscata fuscata, Pyruvate kinase 
isozymes M1 M2 OS, Nucleolin OS Pongo abelii, Pyruvate kinase 
isozyme M1 OS Pongo abelii, Catalase OS, WD repeat containing protein 
1 OS 
Dolichyl diphosphooligosaccharide protein glycosyltransferase subunit 2 
OS, WD repeat containing protein 1, T complex protein 1 subunit zeta 
OS, Heterogeneous nuclear ribonucleoprotein L OS  
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7 Adenylyl cyclase associated protein 1, Tubulin alpha 1B chain OS 
Meriones unguiculatus, Protein disulfide isomerase A3 OS Pongo abelii, 
Calreticulin OS, Glucose 6 phosphate isomerase OS, T complex protein 1 
subunit delta OS Bos Taurus, Plastin 2 OS, Coronin 1A OS Mus 
musculus, Pre mRNA processing factor 19 OS 
8 Alpha enolase OS Pongo abelii, Elongation factor 1 alpha 1, Actin muscle 
OS Pisaster ochraceus, Actin cytoplasmic type 5 OS Xenopus laevis, 
Adenylyl cyclase associated protein 1 OS Pongo abelii, Obg like ATPase 
1 OS Bos Taurus, Ribonuclease inhibitor OS Pan troglodytes, 6 
phosphogluconate dehydrogenase decarboxylating OS,Elongation factor 
Tu mitochondrial OS, Nuclease sensitive element binding protein 1 OS 
Bos Taurus, Eukaryotic initiation factor 4A I OS, 6 phosphogluconate 
dehydrogenase decarboxylating OS Mus musculus, Rab GDP dissociation 
inhibitor beta OS, Fumarate hydratase mitochondrial OS Macaca 
fascicularis, Elongation factor 1 gamma OS Equus caballus, Tubulin beta 
5 chain OS Bos taurus 
9 Actin cytoplasmic type 5 OS Xenopus laevis PE, Elongation factor 1 
alpha 1 OS Gallus gallus, Phosphoglycerate kinase 1 OS Pan troglodytes, 
Elongation factor 1 alpha 1 OS Equus caballus, 40S ribosomal protein SA 
OS Taeniopygia guttata, Heterogeneous nuclear ribonucleoprotein D0 OS, 
Interleukin enhancer binding factor 2 OS Mus musculus  
10 Fructose bisphosphate aldolase A OS, Actin cytoplasmic A4 OS Bombyx 
mori, Elongation factor 1 delta OS, Guanine nucleotide binding protein G 
i subunit alpha 2 OS, Activator of 90 kDa heat shock protein ATPase 
homolog 1 OS, Actin related protein 3 OS Pongo abelii, Protein disulfide 
isomerase A6 OS 
11 Actin cytoplasmic 1 OS Xenopus laevis, 60S acidic ribosomal protein P0 
OS, Heterogeneous nuclear ribonucleoproteins A2 B1 OS Mus musculus, 
LIM and SH3 domain protein 1, Alpha enolase OS Pongo abelii, DNA 
apurinic or apyrimidinic site lyase OS, Pyridoxal kinase OS, Fructose 1 6 
bisphosphatase 1 OS, Eukaryotic translation initiation factor 2 subunit 1, 
Biliverdin reductase A, L lactate dehydrogenase B chain OS Macaca 
fascicularis 
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12 Glyceraldehyde 3 phosphate dehydrogenase, L lactate dehydrogenase B 
chain, Malate dehydrogenase cytoplasmic OS, Malate dehydrogenase 
mitochondrial OS Bos Taurus, Tropomyosin alpha 3 chain OS Rattus 
norvegicus, Heterogeneous nuclear ribonucleoproteins A2 B1 OS Pongo 
abelii, DNA apurinic or apyrimidinic site lyase OS Mus musculus, 
Heterogeneous nuclear ribonucleoprotein A1 OS Pan troglodytes, DNA 
apurinic or apyrimidinic site lyase, Serine threonine protein phosphatase 
2A catalytic subunit alpha isoform OS Oryctolagus cuniculus, Annexin 
A1 OS Pongo abelii 
13 Actin cytoplasmic 1 OS Xenopus tropicalis, Carbonic anhydrase 2 OS, 14 
3 3 protein zeta delta OS Pongo abelii, 14 3 3 protein beta alpha OS, Heat 
shock protein beta 1 OS, Phosphoglycerate mutase 1 OS Rattus 
norvegicus, 6 phosphogluconolactonase OS, 14 3 3 like protein OS Pisum 
sativum PE 2 SV 1, ADP ATP translocase 1 OS Bos Taurus, Adenylate 
kinase 2 mitochondrial OS Pongo abelii, Catechol O methyltransferase 
OS, Peroxiredoxin 4 OS, 6 phosphogluconolactonase OS Mus musculus, 
Eukaryotic translation initiation factor 6 OS, Purine nucleoside 
phosphorylase OS, U2 small nuclear ribonucleoprotein A OS. 
 
 
6.3 CONCLUSION 
Taken together, these findings confirm that MDI crosses cell membranes and react 
with intracellular proteins. It also reacts with membrane proteins. The entry of MDI 
into the cell is a passive process because co-incubation of THP-1 cells with 
cytochalasin D, a microtubule inhibitor, did not change the amount of MDI 
conjugation in the cytoplasm. This passive entry of MDI is a fast process that takes 
place in minutes rather than hours and it is plausible that MDI sensitization and the 
ultimate development of dNCO asthma can proceed through a cell-mediated 
mechanism independent of the production of dNCO specific antibodies. There is 
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ongoing work that involves running 2-dimensional gel electrophoresis and western 
blot analysis using an MDI specific monoclonal antibody (IgG).  
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